Patent Grant
11547852
All publications and patent applications mentioned in this specification are herein incorporated by reference in their entirety to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
Embodiments of the invention relate generally to neuromodulation of the vagus nerve for the treatment of inflammation.
Some neuromodulation devices have the ability to modulate their own stimulation settings quickly based on immediate feedback from target tissue (e.g. muscle) that they are stimulating, since the target tissue responds quickly to stimulation. For example, electromyography (EMG) can be used to record and evaluate the electrical activity of muscles, which provides information regarding the activation level and/or recruitment of the muscles. This information can be processed and used to modulate the neurostimulation parameters applied to the muscles, thereby improving the efficacy of the stimulation device.
Vagus nerve stimulation (VNS) for the treatment of chronic inflammatory diseases, on the other hand, is not easily programmed for optimal result, as decreases in inflammation take hours to days to manifest. Consequently, it would be desirable to identify alternative markers or surrogates that indicate activation of the cholinergic anti-inflammatory pathway by VNS. In addition, it would be desirable to use these alternative markers or surrogates to identify patients that may be suitable for receiving VNS therapy. Furthermore, it would be desirable to directly modulate these markers or surrogates as an alternative or supplemental way to treat inflammation.
In general, described herein are methods and apparatuses (including devices, systems, implants, etc.) for treatment of inflammatory disorders. In particular, described herein are methods of using one or more patient metrics (e.g., biomarkers) alone or, in particular, in combination, to determine if a patient is a good candidate for vagus nerve stimulation and/or to modify or modulate the therapeutic stimulation applied.
For example, described herein are methods for screening or prescreening a patient to determine if the patient is a good candidate for implantable vagus nerve stimulation, prior to stimulation. In general, a metric (e.g., biomarker, such as regulatory T cell level, inflammatory biomarker signal, heart rate variability, etc.) may be taken prior to a vagus nerve stimulation (either internal or external) to provide a baseline value of the one or more metrics, and a vagus nerve stimulation (such as a VNS that would typically result in a modulation of inflammation in a typically responsive patient) may be applied and the same metric(s) taken from the patient immediately or at one or more time intervals thereafter (e.g., within the first hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 12 hours, 16 hours, 20 hours, 24 hours, 36 hours, 40 hours, 48 hours, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, one month, 2 months, three months, etc.). The baseline and post-VNS results may be compared. Alternatively, a running level of the one or more metrics may be monitored to modulate the applied VNS.
When used as a screening technique, a patient may be determined to be a responder (high responder, moderate responder, low responder and/or non-responder) and thereafter stimulated at an appropriate level based on a comparison between one or more baseline metrics to the metrics following vagus nerve stimulation of the patient, or an alternative or supplemental therapy may be applied. The vagus nerve stimulation may be applied externally and/or non-invasively, e.g., by ultrasound or other mechanical stimulation, transcutaneously, including electrically, magnetically (e.g., TES), etc., or invasively, including via one or more needle electrode or the like. Insertion and/or implantation may therefore be performed based on the magnitude of the response.
In addition, vagus nerve stimulation may be set or modified for a patient based on feedback from one or more (and particularly combinations of) metrics. Described herein are biomarker metrics, such as memory T cell levels, as well as physiological markers, and/or activity markers. Physiological markers may include heart rate and/or hear rate variability, and activity markers may include one or more activity level. In particular, described herein are apparatuses adapted to received and/or record metrics that may be used to set, adjust or modify stimulation parameters in a closed loop, semi-closed loop, and/or open loop manner. Any of the vagus nerve stimulators (neurostimulators) described herein may be adapted to determine, record or receive metrics from one or more biomarker, activity level or physiological marker, and may store, transmit, analysis, and/or apply control logic to adjust the behavior of the vagus nerve stimulator based on the one or more metrics measured from the patient.
For example, described herein are methods and apparatuses for treatment of inflammation using vagus nerve stimulation (VNS). In some variations, the one or more metrics used to screen a patient to determine if they would benefit from an implantable neurostimulator, or to modulate or modify the activity of an implanted neurostimulator in a patient having a device, may include the level or ratio of regulatory T cells. Regulatory T cells constitute one immune regulatory cell population in the body. Tregs cells can be characterized broadly into two groups, naïve Tregs (nTregs), and memory Tregs (mTregs). nTregs are precursors to mTregs that have not yet been exposed to their cognate antigen(s). Once nTregs have been exposed to their cognate antigen(s), they can become activated and may further develop into mTregs. mTregs can suppress and/or down regulate the immune response, including the inflammatory response, by secreting various suppressive cytokines and molecules that act on effector T cells and dendritic cells.
VNS has been shown to generally be effective in reducing inflammation. Surprisingly, the inventors have herein found that, in some subjects, the application of VNS also increases the amount of mTregs. The increase in mTregs is surprising because VNS has been shown to reducing inflammation and Treg cells are typically activated in response to inflammation. In those subjects where the application of VNS increased their blood concentration of mTregs (termed moderate or good responders), they also noted an improvement of their inflammation symptoms compared to individuals in which the application of VNS did not affect their concentration of mTregs (relative to nTregs) and VNS may also not have greatly increased their inflammation symptoms; these individuals were labeled non-responders.
Thus, in one example of a method of screening patients may include examining the patients Regulatory T cell response before (baseline) and after vagus nerve stimulation. For example, described herein are methods of preliminary testing of subjects for their potential responsiveness to VNS therapy prior to implanting an implantable stimulation device. Preliminary test may be largely non-invasive or minimally-invasive and may include, e.g., either mechanical or electrical stimulation to a region of the subject's body that would stimulate a branch of the vagus nerve. A baseline of the subject's Treg cell concentration may be obtained. Qualitative evaluation of the subject's inflammation symptoms may also be recorded. After applying the VNS, a measure of the subject's Treg cells concentration may be determined. Additional assessment of the subject's inflammation symptoms may also be evaluated. Candidate for whom a robust Treg response is seen may be implanted. Further the initial stimulation level may be set based in part on the results of the metric (e.g., Treg cell effect); more robust responders may have lower and/or less frequent stimulation applied, while less robust responders may have higher and/or more frequent stimulation applied. Upon determination that the subject is a viable candidate for VNS, the microstimulator may be implanted around a cervical portion of the subject's vagus nerve. The microstimulator may be rechargeable using a charger configured to be worn around the subject's neck, for example. VNS may be applied in a predetermined regimen and repeated over a course of days or weeks. The concentration of the subject's Treg cells may be recorded and the subject's inflammation symptoms may also be accessed.
In some embodiments, a method for treating chronic inflammation in a subject is provided. The method can include stimulating the subject's vagus nerve with an electrical stimulation; modulating a level of memory T regulatory cells in the subject with the electrical stimulation; and reducing a level of inflammation in the patient.
In some embodiments, the method further includes obtaining a baseline level of memory T regulatory cells in the subject; and obtaining a post-stimulation level of memory T regulatory cells in the subject.
In some embodiments, the method further includes comparing the baseline level of memory T regulatory cells to the post-stimulation level; and adjusting at least one parameter of the electrical stimulation based on the step of comparing the baseline level of memory T regulatory cells to the post-stimulation level.
In some embodiments, the at least one parameter is adjusted until the post-stimulation level is greater than the baseline level by at least a predetermined amount.
In some embodiments, the predetermined amount is 10 percent.
In some embodiments, the step of adjusting at least one parameter of the electrical stimulation includes increasing the amplitude of the electrical stimulation.
In some embodiments, the electrical stimulation is delivered from an implanted microstimulator.
In some embodiments, the electrical stimulation is delivered from a transcutaneous electrical nerve stimulator.
In some embodiments, a method for screening a subject for suitability for vagus nerve stimulation treatment is provided. The method can include obtaining a baseline level of memory T regulatory cells in the subject; stimulating the subject's vagus nerve; obtaining a post-stimulation level of memory T regulatory cells in the subject; and comparing the baseline level to the post-stimulation level to determine whether the subject is suitable for vagus nerve stimulation treatment.
In some embodiments, the step of comparing the baseline level to the post-stimulation level includes determining whether the post-stimulation level exceeds the baseline level by a predetermined amount.
In some embodiments, the predetermined amount is at least 10 percent.
In some embodiments, the step of obtaining a baseline level of memory T regulatory cells includes determining the number of CD4+CD25+CD127LowCD45RO+ cells in a sample of blood from the subject.
In some embodiments, the step of obtaining a baseline level of memory T regulatory cells includes determining the expression of FOXP3 in a sample of blood from the subject.
In some embodiments, the step of stimulating the subject's vagus nerve comprises noninvasively stimulating the vagus nerve.
In some embodiments, the noninvasive stimulation is electrical stimulation.
In some embodiments, the noninvasive stimulation is mechanical stimulation.
In some embodiments, the mechanical stimulation is performed on the patient's ear.
In some embodiments, the step of stimulating the subject's vagus nerve comprises minimally invasively stimulating the vagus nerve.
In some embodiments, the minimally invasive stimulation includes stimulation from a needle electrode.
In some embodiments, the method further includes implanting a vagus nerve stimulator in the subject based at least in part on the step of comparing the baseline level to the post-stimulation level.
In some embodiments, a method of setting a dosage level for electrically stimulating a subject's vagus nerve for treating inflammation is provided. The method can include measuring a baseline level of memory T regulatory cells in a sample of the subject's blood; stimulating the subject's vagus nerve with an electrical stimulation; measuring a post-stimulation level of memory T regulatory cells in a sample of the patient's blood taken after the step of stimulating the subject's vagus nerve; comparing the baseline level of memory T regulatory cells to the post-stimulation level; and adjusting at least one parameter of the electrical stimulation based on the step of comparing the baseline level of memory T regulatory cells to the post-stimulation level.
In some embodiments, the at least one parameter is adjusted until the post-stimulation level is greater than the baseline level by at least a predetermined amount.
In some embodiments, the step of adjusting at least one parameter of the electrical stimulation includes increasing the amplitude of the electrical stimulation.
The methods and apparatuses described herein may include or be adapted for modulation of a therapeutic stimulation applied by any of the neurostimulator (e.g., microstimulator, microregulators, MRs, etc.) described herein based on one or more sensors detecting body activity and/or personal wellness. For example, described herein apparatuses (devices and systems) adapted to receive information about body movement (body motion, heart rate, HRV, etc.) and/or wellness (subjective, patient reported) and this information may be used to modulate the VNS applied by the apparatus.
In some variations the implant includes one or more sensor (e.g., accelerometers) that may be adapted for use in a control as described herein, including closed-loop, semi-closed loop, or open-loop (e.g., in which a patient, physician and/or technician may receive information on the metric to help guide or suggest treatment options). In some variations, the apparatus may receive information from other sources of data, including third-party databases. This data may be received by the implant and/or charger and/or programmer/controller (or a device integrating two or more of these functions) and may be used to calculate a modification of the current/ongoing VNS protocol and/or to initiate and/or to terminate the application of a VNS protocol.
Any of the apparatuses described herein may be adapted or configured to use hear rate variability (HRV) as a metric alone or in combination with other metrics. Heart rate variability may be measured from the same electrodes applying the VNS of the microstimulator. Surprisingly, although the electrodes are in electrical contact with the nerve, the inventors have herein shown that an electrocardiograph (ECG) signal, and particularly the R peak of the signal, may be recorded from the electrodes of a microstimulator (e.g., across a bipolar electrode on the vagus) within the nerve cuff holding the microstimulator to the cervical vagus nerve. Thus, HRV may be determined in a patient at various times before and immediately after VNS using a microstimulator connected to the vagus nerve by appropriately filtering (e.g., high pass filtering at an appropriate frequency such as 10 Hz) and analysis of a recorded signal. Alternatively or additionally, HRV may be determined by the use of an accelerometer, a microphone, or the like, which may also be included as part of the microstimulator. In some variations, a separate measure of a metric (including, but not limited to HRV) may be determined using a device that is separate from the microstimulator, and this data may be fed to the microstimulator or to a device in communication (e.g., remote controller) with the microstimulator.
For example, when HRV is used to modulate activity and/or screen a patient, the VNS may be modulated by increasing or decreasing the frequency and/or intensity of stimulation based on HRV. Heart rate variability may be determined by the implant, or by a controller in communication with the implant (e.g., smartwatch, smartphone, etc.), and may be continuously or periodically determined. In particular the apparatuses described herein may be configured to determine HRV for a patient when the patient is at rest; thus, the measure of HRV may be taken based on one or more of: time of day and/or patient activity level. For example, the HRV measure may be taken when the patient is not moving (e.g., sleeping, etc.) based on an internal or external accelerometer or any other motion/vibration monitor in communication with the apparatus. Alternatively or additionally, the apparatus may be configured to determine HRV a fixed time period (or within a predetermined window of time) following VNS, such as within 1-120 minutes, within 2-100 minutes, etc. following VNS, and/or when the patient is at rest following this stimulation, which may be determined or confirmed by an activity monitor.
Alternatively or additionally, respiratory information may be measured by an implantable apparatus and used a metric or in conjunction with any of the metrics described herein. For example, if an accelerometer is included in the device, respiratory movements and/or sounds may be used to p provide a measure of respiratory rates.
Also described herein are methods for treating inflammation in a subject based on one or more of the metrics (e.g., heart rate, activity, body temperature, etc.) described herein. For example, described herein are methods for treating inflammation comprising: measuring a first heart rate variability from the subject using an electrode of an implantable microstimulator, wherein the electrode is in electrical contact with the subject's vagus nerve; applying a first electrical stimulation to the subject's vagus nerve from the electrode; measuring a second heart rate variability from the subject after the first electrical stimulation; and applying a second electrical stimulation to the subject's vagus nerve based on the first heart rate variability and the second heart rate variability.
The method may also include measuring a second metric from the patient, and further wherein applying the second electrical stimulation is based on the first heart rate variability, the second heart rate variability and the second metric. The second metric may comprise one or more of: temperature, activity, cytokine level, and memory T cell level. Applying the second electrical stimulation to the subject may comprise increasing or decreasing the stimulation based on the first heart rate variability and the second heart rate variability, wherein increasing or decreasing the stimulation may comprise increasing or decreasing one or more of: the frequency of stimulation, the duration of stimulation, the burst duration, the amplitude of electrical stimulation, and the peak-to-peak voltage of the stimulation.
Applying the second electrical stimulation to the subject's vagus nerve based on the first heart rate variability and the second heart rate variability may comprise determining a ratio of high frequency to low frequency components of heart rate variability. The method of claim 1, wherein the second electrical stimulation is applied after an off-period of between 30 minutes and 24 hours. The electrode may be in contact with the subject's vagus nerve in the patient's cervical region. The low frequency (LF) band (e.g., approximately 0.04-0.15 Hz) may be related to both sympathetic and parasympathetic modulation, and the high frequency (HF) band (e.g., approximately 0.15-0.40 Hz, or 0.18 to 0.4 Hz) may be governed almost exclusively by parasympathetic effects. The ratio of LF to HF power may be used as a metric of sympathetic/parasympathetic balance. It is important to note, however, that a driver of HRV in the HF band may be respiration. The magnitude of HF power may be highly dependent on the depth of respiration, which often varies greatly from one recording epoch to another. HRV may also be referred to as “cycle length variability”, “RR variability” (where R is a point corresponding to the peak of the QRS complex of the ECG wave; and RR is the interval between successive Rs), and “heart period variability”. HRV may be estimated by frequency domain (e.g., Fourier transform, including FFT) or time-domain methods (e.g., standard deviation of beat-to-beat intervals, root mean square of successive differences between adjacent beat-to-beat intervals, standard deviation of successive differences between adjacent beat-to-beat intervals, etc.
Also described herein are leadless, implantable microstimulator apparatus for treating chronic inflammation in a patient, the apparatus comprising: a housing having a channel through which a nerve may pass; at least two electrically conductive contacts; a motion sensor within the housing, the motion sensor configured to measure physical activity of the patient; a power source (e.g., battery, capacitor, etc.) within the housing; an electronic assembly within the housing, wherein the electronic assembly comprises a controller configured to apply stimulation to the vagus nerve from the electrically conductive contacts and to measure heart rate variability from the electrically conductive contacts; further wherein the controller is configured to adjust the applied stimulation based on the measurement of heart rate variability; and a protection an orientation (POD) cuff configured to hold the housing over the nerve so that the nerve is in electrical communication with the electrically conductive contacts. The motion sensor may comprise an accelerometer.
The controller may be configured to adjust the stimulation based on the measurement of heart rate variability and the measured physical activity. The controller may be configured to measure heart rate variability when the patient is at rest based on the motion sensor. Based on the measurement of heart rate variability, the controller may adjust one or more of: a stimulation amplitude, a stimulation duration, and a stimulation frequency of application. The controller may be configured increase one or more stimulation parameters when a decrease in physical activity is measured by the accelerometer.
Also described herein are methods for treating inflammation in a subject, the method comprising: measuring a first level of memory T regulatory cells in the subject; applying a first stimulation to the subject's vagus nerve; measuring a second level of memory T regulatory cells in the subject after the first stimulation; and applying a second stimulation to the subject's vagus nerve based on the first and second levels of memory T regulatory cells measured.
The method may also include comparing the first level of memory T regulatory cells to the second level of memory T regulatory cells. The second stimulation may be greater than than the first stimulation by at least a predetermined amount in one or more of: the frequency of stimulation, the duration of stimulation, the burst duration, the amplitude of electrical stimulation, and the peak-to-peak voltage of the stimulation. The second stimulation may be less than the first stimulation by at least a predetermined amount in one or more of: the frequency of stimulation, the duration of stimulation, the burst duration, the amplitude of electrical stimulation, and the peak-to-peak voltage of the stimulation. The predetermined amount may be approximately 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, etc.
Applying the second stimulation to the subject's vagus nerve may comprise applying electrical stimulation from an implanted microstimulator. Applying the first stimulation to the subject's vagus nerve may comprise applying a non-invasive stimulation to the subject's vagus nerve.
Measuring the first (and/or second) level of memory T regulatory cells may comprises determining a level of CD4+CD25+CD127LowCD45RO+ cells in a sample of blood from the subject. Measuring the first and/or second level of memory T regulatory cells may comprise determining a level of expression of FOXP3 in a sample of blood from the subject.
Applying the first stimulation to the subject's vagus nerve may comprises applying a minimally-invasive stimulation to the subject's vagus nerve. For example, the minimally invasive stimulation may comprise stimulation from a needle electrode.
Also described here are methods of setting a dosage level for electrically stimulating a subject's vagus nerve for treating inflammation, the method comprising: measuring a baseline level of memory T regulatory cells in a sample of the subject's blood; applying a first stimulation to the subject's vagus nerve; measuring a post-stimulation level of memory T regulatory cells in a sample of the patient's blood taken after applying the first stimulation to the subject's vagus nerve; comparing the baseline level of memory T regulatory cells to the post-stimulation level; adjusting at least one parameter of the first stimulation based on the baseline level of memory T regulatory cells and the post-stimulation level of memory T regulatory cells; and applying a second stimulation to the subject's vagus nerve using the adjusted at least one parameter.
The novel features of the invention are set forth with particularity in the claims that follow. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
Vagus nerve stimulation (VNS) has been shown to modulate a variety biological processes in the body, including the inflammatory response. Although VNS stimulation may modulate the inflammatory response in some or most patients, the level of response to the patient may vary based on the applied VNS. A variety of techniques can be used to attempt to better identify or predict which patients may respond better to VNS. For example, the level of cytokines can be measured before and after VNS in an assay on the patient's blood or in a cell based assay. A reduction in the level or release of an inflammatory cytokine, such as TNF for example, may indicate that the patient is responding to VNS, and/or may give an indication of the level of response.
Described herein are methods and apparatuses in which one or more metrics, including biomarker metrics, activity metrics, physiological metrics, or the like, may be used to determine which patients may be treated by VNS and/or the dose or level of applied VNS either initially and/or in an ongoing manner. Thus, described herein are apparatuses (devices, systems, implants, etc.) for detecting one or more metric and for modulating a VNS therapy to treat an inflammatory disorder based on the one or more metric.
Vagus Nerve Stimulation System
Systems for electrically stimulating one or more nerves to treat chronic inflammation may include an implantable, wireless microstimulator such as those described herein and an external charging device (which may be referred to as a charging wand, charger, or energizer). In some variations the system also includes a controller (sometimes referred to herein as a “prescription pad”, which may be an external processor in communication with the implanted microstimulator, such as a smartphone, smartwatch, etc.) that helps control and regulate the dose delivered by the system. The microstimulator may be secured in position using a securing device (which may be referred to as a “POD”) to hold the microstimulator in position around or adjacent to a nerve. These microstimulator s may be designed and adapted for treatment of chronic inflammation, and may be configured specifically for such use. Thus, an implantable microstimulator may be small, and adapted for the low duty-cycle stimulation to modulate inflammation. For example, the implantable microstimulator may hold a relatively small amount of power over weeks or even months and discharge it at a rate sufficient to modulate the anti-inflammatory pathway without significantly depressing heart rate or triggering any number of unwanted effects from the vagus nerve or other neural connections. Any of the nerves of the inflammatory reflex, including the vagus nerve, may be treated as described herein using the systems described.
For example,
In general, the systems described herein may be configured to apply electrical stimulation at a minimum level necessary to modulate the inflammatory reflex (e.g., modulating cytokine release) characterized by the Chronaxie and rheobase. Chronaxie typically refers to the minimum time over which an electric current double the strength of the rheobase needs to be applied in order to stimulate the neuron. Rheobase is the minimal electrical current of infinite duration that results in an action potential. As used herein, cytokines refer to a category of signaling proteins and glycoproteins that, like hormones and neurotransmitters, are used extensively in cellular communication.
The NCAP Systems described herein are typically intended for the treatment of chronic inflammation through the use of implanted neural stimulation devices (microstimulators) to affect the Neural Stimulation of the Cholinergic Anti-inflammatory Pathway (NCAP) as a potential therapeutic intervention for rheumatologic and other inflammation-mediated diseases and disorders. Neurostimulation of the Cholinergic Anti-inflammatory Pathway (NCAP) has been shown to modulate inflammation. Thus, the treatment and management of symptoms manifested from the onset of disease (e.g., inflammatory disease) is based upon the concept of modulating the Cholinergic Anti-inflammatory Pathway. The NCAP pathway normally maintains precise restraint of the circulating immune cells. As used herein, the CAP is a reflex that utilizes cholinergic nerve signals traveling via the Vagus nerve between the brain, chemoreceptors, and the reticuloendothelial system (e.g., spleen, liver). Local release of pro-inflammatory cytokines (e.g., tumor necrosis factor or TNF) from resident immune cells is inhibited by the efferent, or indirectly by afferent vagus nerve signals. NCAP causes important changes in the function and microenvironment of the spleen, liver and other reticuloendothelial organs. Leukocytes which circulate systemically become “educated” as they traverse the liver and spleen are thereby functionally down regulated by the affected environment of the reticuloendothelial system. This effect can potentially occur even in the absence of an inflammatory condition.
Under this model, remote inflammation is then dampened by down-regulated cytokine levels. Stimulation of the vagus nerve with a specific regiment of electrical pulses regulates production of pro-inflammatory cytokines. In-turn, the down regulation of these cytokines may reduce localized inflammation in joints and other organs of patients with autoimmune and inflammatory disorders. Furthermore, as will be described in greater detail herein, it appears that VNS, in a subset of patients, has the added beneficial effect of promoting CD4+CD25+Foxp3+Treg cells that may lead to new methods of treating autoimmune disorders and mitigating tissue rejection in organ transplant cases.
The NCAP System includes a neurostimulator that may trigger the CAP by stimulating the cervical vagus nerve. The NCAP System issues a timed burst of current controlled pulses with sufficient amplitude to trigger the CAP at a particular interval. These two parameters, Dose Amplitude and Dose Interval, may be used by a clinician to adjust the device. For example, the clinician may set the Dose Amplitude by modifying the current level. The Dose Interval may be set by changing the duration between Doses (e.g. 12, 24, 48 hours).
In some variations, dose amplitude may be set to within the Therapy Window. The Therapy window is defined as the lower limit of current necessary to trigger the CAP, and the upper limit is the level at which the Patient feels uncomfortable. The lower limit is called the Threshold (T), and the uncomfortable level is called Upper Comfort Level (UCL).
Dose Amplitude thresholds are nonlinearly dependent upon Current (I), Pulse width (PW), Pulse Frequency (PF), and Burst Duration (BD). Amplitude is primarily set by charge (Q), that is Current (I)×Pulse width (PW). In neurostimulation applications current has the most linear relationship when determining thresholds and working within the therapy window. Therefore, the clinician may modify Dose Amplitude by modifying current. The other parameters are held to experimentally determined defaults. Pulse width is selected to be narrow enough to minimize muscle recruitment and wide enough to be well above the chronaxie of the targeted neurons. Stimulus duration and pulse frequency was determined experimentally in Preclinical work.
Dose Interval may be specific for particular diseases and the intensity of diseases experienced by a patient. Our initial research has indicated that the cervical portion of the vagus nerve may be an ideal anatomic location for delivery of stimulation. The nerve runs through the carotid sheath parallel to the internal jugular vein and carotid artery. At this location, excitation thresholds for the vagus are low, and the nerve is surgically accessible. We have not found any significant difference in biomarker modulation (e.g., modulation of cytokines) between right and left. Even though the right vagus is thought to have lower thresholds than the left in triggering cardiac dysrythmias, the thresholds necessary for NCAP are much lower than those expected to cause such dysrythmias. Therefore a device delivering NCAP can safely be applied to either the right or left vagus.
We have also found, surprisingly, that the Therapy Window is maximized on the cervical vagus through the use of a bipolar cuff electrode design. Key parameters of the cuff may be: spacing and shielding of the contacts. For example, the contact points or bands may be spaced 1-2 diameters of the vagus nerve apart, and it may be helpful to shield current from these contacts from other nearby structures susceptible to inadvertent triggering. The cuff may be further optimized by using bands which are as long and wide as possible to reduce neurostimulator power requirements.
Thus, any variations of the systems described herein (e.g., the NCAP system) may be implemented with a Cuff, Lead and Implantable Pulse Generation (IPG), or a Leadless Cuff. The preferred implementation is a leadless cuff implemented by a microstimulator with integral electrode contacts in intimate contact with the nerve and contained within a Protection and Orientation Device (POD). This is illustrated in
The circuitry of any of the microstimulators described herein may include a motion detector (e.g., accelerometer or any other vibration sensor/detector, particularly those having low power requirements). In addition or alternatively, any of these apparatuses may include a microphone for detecting vibrations (including auscultation), a temperature sensor for detecting patient temperature (e.g., of nerve, body, blood, etc.), or the like. Although one or more additional electrical sensors (electrodes) may be used for detecting electrical potentials from the body, in some variations the same electrodes used to apply VNS may be configured to record electrical activity, and in particular the microstimulator may be configured to determine electrocardiogram (ECG) data, including heart rate and heart rate variability. In some variations the one or more sensors may be present on the microstimulator and/or the POD. Alternatively or additionally, the microstimulator may be configured to receive data regarding one or more metric from a sensor that is separate from the microstimulator, e.g., via the wireless radio (e.g., Bluetooth, etc.) within the microstimulator; this data may be analyzed and/or aggregated with other data for storage, transmission and/or analysis by the microstimulator, including in particular for modulation of the applied VNS.
Referring back to
As described in more detail in U.S. patent application Ser. No. 12/874,171, titled “PRESCRIPTION PAD FOR TREATMENT OF INFLAMMATORY DISORDERS”, filed on Mar. 3, 2011, Publication No. US-2011-0054569-A1, incorporated by reference in its entirety herein, the Prescription Pad may incorporate workflows in a simplified interface and provide data collection facilities that can be transferred to an external database utilizing commercially robust and compliant methods and procedures. In use, the system may be recommended for use by a clinician after assessing a patient; the clinician may determine that treatment of chronic inflammation is warranted. The clinician may then refer the patient to an interventional doctor to implant the microstimulator. Thereafter then clinician (or another clinician) may monitor the patient and adjust the device via a wireless programmer (e.g. prescription pad). The clinician may be trained in the diagnosis and treatment procedures for autoimmune and inflammatory disorders; the interventional placement of the system may be performed by a surgeon trained in the implantation of active neurostimulation devices, with a sufficient depth of knowledge and experience regarding cervical and vagal anatomy, experienced in performing surgical dissections in and around the carotid sheath.
The system may output signals, including diagnostics, historical treatment schedules, or the like. The clinician may adjust the device during flares and/or during routine visits. Examples of implantation of the microstimulator were provided in U.S. patent application Ser. No. 12/874,171, titled “PRESCRIPTION PAD FOR TREATMENT OF INFLAMMATORY DISORDERS”, filed on Mar. 3, 2011, Publication No. US-2011-0054569-A1. For example, the implant may be inserted by making an incision in the skin (e.g., ≈3 cm) along Lange's crease between the Facial Vein and the Omohyoid muscle, reflecting the Sternocleidomastoid and gaining access to the carotid sheath. The IJV may be displaced, and the vagus may be dissected from the carotid wall (<2 cm). A sizing tool may be used to measure the vagus, and an appropriate Microstimulator and POD Kit (small, medium, large) may be selected. The POD may then be inserted under nerve with the POD opening facing the surgeon, so that the microstimulator can be inserted inside POD so that the microstimulator contacts capture the vagus. The POD may then be sutured shut. In some variations a Surgical Tester may be used to activate the microstimulator and perform system integrity and impedance checks, and shut the microstimulator off, during or after the implantation. In other variations the surgical tester may be unnecessary, as described in greater detail below. A schematic of the internal components of the microstimulator and the charger can be seen in
A physician may use the Patient Charger to activate the microstimulator, perform integrity checks, and assure sufficient battery reserve exists. Electrodes may be conditioned with sub-threshold current and impedances may be measured. A Physician may charge the microstimulator. In some variations a separate charger (e.g., an “energizer”) may be used by the patient directly, separate from the controller the physician may use. Alternatively, the patient controller may include controls for operation by a physician; the system may lock out non-physicians (e.g., those not having a key, code, or other security pass) from operating or modifying the controls.
In general, a physician may establish safe dosage levels. The physician may slowly increment current level to establish a maximum limit (Upper Comfort Limit). This current level may be used to set the Dosage Level. The exact procedure may be determined during this clinical phase.
The Physician may also specify dosing parameters that specify dosage levels and dosage intervals. The device may contain several concurrent dosing programs which may be used to acclimate the patient to stimulus, gradually increase dosage until efficacy is achieved, reset tachyphylaxis, or deal with unique patient situations.
In some variations, the Prescription Pad may be configured to handle multiple patients and may index their data by the microstimulator Serial Number. For example, a Prescription Pad may handle up to 100,000 patients and 10,000 records per patient, and may store the data in its local memory and may be backed up on an external database. In some variations, during each charging session, accumulated even log contents will be uploaded to the Patient Charger for later transfer to Prescription Pad. The data may or may not be cleared from the microstimulator. For example,
The microstimulators described herein are configured for implantation and stimulation of the cholinergic anti-inflammatory pathway, and especially the vagus nerve. In particular the microstimulators described herein are configured for implantation in the cervical region of the vagus nerve to provide extremely low duty-cycle stimulation sufficient to modulate inflammation. These microstimulators may be adapted for this purpose by including one or more of the following characteristics, which are described in greater detail herein: the conductive capsule ends of the micro stimulator may be routed to separate electrodes; the conductive capsule ends may be made from resistive titanium alloy to reduce magnetic field absorption; the electrodes may be positioned in a polymer saddle; the device includes a suspension (e.g., components may be suspended by metal clips) to safeguard the electronics from mechanical forces and shock; the device may include an H-bridge current source with capacitor isolation on both leads; the device may include a built in temperature sensor that stops energy absorption from any RF source by detuning the resonator; the device may include a built-in overvoltage sensor to stop energy absorption from any RF source by detuning resonator; the system may include DACs that are used to calibrate silicon for battery charging and protection; the system may include DACs that are used to calibrate silicon for precision timing rather than relying on crystal oscillator; the system may include a load stabilizer that maintains constant load so that inductive system can communicate efficiently; the system may include current limiters to prevent a current rush so that the microstimulator will power up smoothly from resonator power source; the system may extract a clock from carrier OR from internal clock; the device may use an ultra-low power accurate RC oscillator that uses stable temperature in body, DAC calibration, and clock adjustment during charging process; the device may use a solid state LIPON battery that allows fast recharge, supports many cycles, cannot explode, and is easy to charge with constant voltage; and the device may include a resonator that uses low frequency material designed not to absorb energy by high frequency sources such as MRI and Diathermy devices.
Many of these improvements permit the device to have an extremely small footprint and power consumption, while still effectively modulating the vagus nerve.
In some variations, including those described above, the microstimulator consists of a ceramic body with hermetically sealed titanium-niobium ends and integral platinum-iridium electrodes attached. The microstimulator may be designed to fit within a POD 309, as shown in
As mentioned above, some of the device variations described herein may be used with a POD to secure the implant (e.g., the leadless/wireless microstimulator implant) in position within the cervical region of the vagus nerve so that the device may be programmed and recharged by the charger/programmer (e.g., “energizer”). For example,
In some variations, the microstimulator may have a bipolar stimulation current source that produce as stimulation dose with the characteristics shown in table 1, below. In some variation, the system may be configured to allow adjustment of the “Advanced Parameters” listed below; in some variations the parameters may be configured so that they are predetermined or pre-set. In some variations, the Advanced Parameters are not adjustable (or shown) to the clinician. All parameters listed in Table 1 are ±5% unless specified otherwise.
The Dosage Interval is defined as the time between Stimulation Doses. In some variations, to support more advanced dosing scenarios, up to four ‘programs’ can run sequentially. Each program has a start date and time and will run until the next program starts. Dosing may be suspended while the Prescription Pad is in Programming Mode. Dosing may typically continue as normal while charging. Programs may be loaded into one of four available slots and can be tested before they start running. Low, Typical, and High Dose schedules may be provided. A continuous application schedule may be available by charging every day, or at some other predetermined charging interval. For example, Table 2 illustrates exemplary properties for low, typical and high dose charging intervals:
The system may also be configured to limit the leakage and maximum and minimum charge densities, to protect the patient, as shown in Table 3:
In some variations, the system may also be configured to allow the following functions (listed in Table 4, below):
As mentioned, one or more metrics (e.g., biomarkers, physiological parameters, etc.) may be measured including measured by the microstimulator and the microstimulator may be both adapted to measure the one or more metrics and/or to modulate the applied VNS based on the measured and/or analyzed metric(s).
For example, described herein are methods and apparatuses for detecting or measuring regulatory T cells (Tregs) and/or memory regulatory T cells (mTregs) either or both to provide a method of screening a patient's sensitive to VNS and/or for modulating the inflammatory response based on modulation of the VNS applied specific to that patient. Tregs are T-cells that are involved in maintaining tolerance to self-antigens, and more generally, the suppression of the immune response. One way Tregs achieve their function is by the suppression or down regulation of the induction and/or proliferation of effector T-cells.
Tregs can be characterized broadly into two groups, naïve Tregs (nTregs), which are CD4+CD25+CD127lowCD45RA+, and memory Tregs (mTregs), which are CD4+CD25+CD127lowCD45RO+. nTregs are precursors to mTregs that have not yet been exposed to their cognate antigen(s). Once nTregs have been exposed to their cognate antigen(s), they can become activated and may further develop into mTregs. mTregs can suppress and/or down regulate the immune response, including the inflammatory response, by secreting various suppressive cytokines and molecules that act on effector T cells and dendritic cells, such as IL-35, IL-10, and/or TGFβ, by metabolic disruption, and/or by inducing cytolysis of effector T cells and dendritic cells.
Furthermore, Treg cells have been found to have phenotypically and functionally heterogeneous populations, where specific subsets of Treg cells need different factors for their differentiation, maintenance, and also function in different inflammatory contexts and tissue. Treg cells can be divided into functionally distinct effector populations based on differential expression of adhesion and chemattractant receptors, those that target lymphoid tissue versus those that target non-lymphoid tissue to prevent inflammatory disease and maintain normal immune homeostasis. Treg cells have been found in a different tissue throughout the body including skin, intestine, lungs, liver, adipose, and skeletal muscle. Because Treg cells are recruited to inflamed tissue (sites) where they function to mitigate autoimmunity, and prevent collateral tissue damage during ongoing inflammation, control of Treg cells may be particularly useful in controlling autoimmune disease and tissue or organ transplanting procedures.
Memory Treg cells, as the name suggests, possess “memory” for encounters with a specific antigen. It has been found that after exposure to a particular antigen, the antigen-specific Treg cells become activated and recruited to the target tissue. After resolving the primary infection/inflammation, these activated Treg cells reside in the tissue even after the termination of the infection and in the absence of antigen. Upon re-encounter of the same antigen these Treg cells, now termed memory Treg cells, suppress a secondary inflammatory response and do so more efficiently than during the initial exposure to that antigen.
Previously disclosed methods have used implantable microstimulator on the Vagus nerve (VNS) to target inflammation. Experiments have shown that VNS can significantly inhibit disease severity by reducing the amount of inflammation and resulting damage. Surprisingly, it was also found that in some subjects treated, the application of VNS also increased the amount of memory Treg cells over a statistically significant amount. The increase in memory Treg cells is surprising because the application of VNS has an inflammation-reducing effect and Treg cells typically are activated and recruited in response to inflammation. Thus, one would expect Treg cell concentrations to decrease, and certainly not increase over the duration of VNS application where there is measurable decrease in overall inflammation. The increase in memory Treg cells in some subjects over the course of the VNS treatment was unexpected.
It would advantageous to harness both the beneficial effects of VNS and the increased presence of Treg cells in those suffering from diseases that cause inflammation, and autoimmune diseases that cause inflammation (such as rheumatoid arthritis).
Described herein are systems and methods of using VNS to modulate mTreg, using the concentration of mTreg to screen for “mTreg” responders to VNS, and using mTreg to set therapeutic dosing parameters for VNS to further decrease inflammatory response within these subjects.
VNS surprisingly resulted in an increase in nTregs and mTregs in some patients, while in other patients VNS fails to significantly increase Tregs; the results are shown in
Turning to
Finally, turning to
In all the data described above, some subjects possessed T regulatory cells, and particularly memory T regulatory cells, that showed moderate to good response to stimulation application, while others possessed T regulatory cells that did not respond to stimulation in any significant way. It would be preferable to determine whether a subject's T regulatory cells, and particularly memory T regulatory cells, are responsive to stimulation prior to implanting the stimulation device around their vagus nerve. Thus, less invasive screening methods may be implemented to determine whether a subject's Treg cells are responsive to stimulation. In such preliminary test, qualitative evaluation of improvements on inflammation may also be assessed. In both preliminary assessments, it is understood that the external stimulation may only have a fraction of the beneficial effects compared to when the stimulation is directly applied to the vagus nerve.
Preliminary testing of Treg cell response to stimulation within subjects may be performed in a minimally-invasive or non-invasive manner. Non-invasive stimulation described herein is non-invasive mechanical stimulation applied at a predetermined range of intensities, frequencies, and duty-cycles. Also, non-invasive electrical stimulation may also be applied. For example, non-invasive stimulation may be through couplers in communication with an actuator that may be part of a stimulation device that is configured to stimulate at least a portion of the subject's ear. In other examples, mechanical actuators or electrical stimulation leads, electrodes, clips, or couplers that allow for stimulation of the peripheral branches of the vagus nerve may be used. In some embodiments, the electrical stimulation can be delivered through the skin to the vagus nerve using a transcutaneous electrical nerve stimulation (TENS) device. The TENS device can be place over any portion of the body which is in proximity to the vagus nerve or one of its branch nerves, such as the ear or neck.
In other embodiments, the minimally invasive electrical stimulation used in the screening test can be delivered directly to the nerve using a needle electrode.
More specifically, mechanical stimulation may be applied to a subject's ear, in particular, the cymba conchae region. Mechanicals stimulation may also be applied to other appropriate regions of the subject's body. In some examples, the non-invasive stimulation may be mechanical stimulation between about 50-500 Hz and having appropriate duration (e.g. less than 5 minutes, less than 3 minutes, less than 1 minute, and so forth), at an appropriate intensity and frequency.
In other examples, preliminary testing may include electrical stimulation applied to the pinna. The pinna region of the ear has little or no hair and several cranial and cervical spinal nerves project to this portion of the ear. Other regions targeted may include vagal nerve endings in the conch of the ear. In some examples, the electrical stimulation may be with frequencies as described herein and, for example, peak intensity of up to 2, 5, 10, 15, or 20 mA. The electrical stimulation may occur every few hours and where the electrical stimulation uses the parameters described herein except that the intensity of the stimulation may be increased up to 2, 5, 10, 15 or 20 mA in order to penetrate through the skin and other tissues to reach the nerve.
The effect of stimulation on the concentration of Treg cells may then be studied. A baseline level of T regulatory cells may first be determined by measuring the amount of T regulatory cells in the subject's blood before stimulation is applied. This may be done with known analytical techniques such as flow cytometry. Other methods of arriving at the concentration of T regulatory cells may be through determining the concentration of associated gene segments and markers within the DNA or RNA of the Treg cells. This may include using known methods for assaying the FOXP3 gene which is centrally involved in the development and function of the Treg cells. Yet another method for determining the concentration of Treg cells may involve challenge with a particular antigen having a known concentration. Once baselines have been taken for a subject, non-invasive or minimally-invasive stimulation may be applied over a given length of time, with a particular frequency, and over a course of time. Changes in Treg cell concentrations, particularly mTreg cell concentrations can be mapped to the application of stimulus. Memory T-regulatory cells can be identified as CD4+CD25+CD127LowCD45RO+ using various techniques and/or can be identified by its expression of the FOXP3 gene. Naïve T-regulatory cells can be identified as CD4+CD25+CD127lowCD45RA+.
Cutoffs may be set for determining whether a subject is responding positively to the stimulation. The cutoffs may be either quantitative (increase in mTreg cells), qualitative (a subject's evaluation of improvement in their inflammation based on EULAR or ACR scoring), or a combination of both. For example, a threshold limit of 20 percent Treg cells above baseline may be correlated to having a positive effect. In other examples, the threshold limit may be set at 10 percent, 30 percent, 40 percent, or 50 percent above baseline to indicate a positive response. It should also be noted that the percent above baseline limit set may also be an average value. Having an average value above baseline will reveal where data is extremely noisy and does not in fact show any positive response even though a few values are above the set threshold.
In some instances, stimulation amplitude, frequency (as in the number of stimulations applied per day), or the “on” period for the stimulation may be step-wise increased or ramped up to determine, for example, if increasing the amplitude or length of time according to Table 1 results in an increase in memory T-regulatory cells. For example, the parameters listed in Table 1 may be adjusted to determine whether altering these parameters might have a measurable effect on the concentration of mTreg cells and/or the level of inflammation experienced by the subject. In some embodiments, one or more parameters can be adjusted until the level of mTreg cells increases by a predetermined amount, such as 10, 20, 30, 40, or 50 percent above a baseline level measured before stimulation. This can be used to set the dosing of an implanted microstimulator.
In implementation, the concentration of memory cells (e.g., mTreg, nTreg or both) may be determined external to an implant and the data provided to the implant, as mentioned (e.g., by flow cytometry). Alternatively, the implant may be configured to measure or detect the level of memory cells or changes in the level(s) of memory cells. For example, the implant may include a microfluidics detector for receiving and analyzing blood, including memory T cells, and/or an immunofluorescence detection/quantification of memory T-cells.
As mentioned above, alternatively or additionally, and other metric, including but not limited to heart rate and heart rate variability may be used as a screen and/or to adjust VNS. Thus, a body and/or wellness sensor may be used to modulate the activity of an implanted neurostimulator (microstimulator). These sensors may be integrated into the implant or they may be separate from the implant, including databases tracking wellness/fitness of the user unrelated to the implant. For example, motion tracking may be used. In some variations an accelerometer can be used to measure patient activity, which may be correlated with the level of inflammation suffered by the patient, and used to modulate one or more stimulation parameters, such as stimulation amplitude, stimulation duration, and the frequency of stimulations. In another example, heart rate and/or heart rate variability can be used to modulate one or more stimulation parameters. Any of the implants described herein may include such a sensor (e.g., accelerometer, etc.) and any of these systems may be adapted to use this sensor information to modulate the applied stimulation.
In some embodiments, one or more sensors can be used to measure various metrics (e.g., physiological parameters such as HR, HRV, respiration rate, body temperature, etc.), which can then be used to modulate vagus nerve stimulation (VNS). For example, a motion sensor (such as an accelerometer) can be used to measure patient activity. Alternatively or additionally, a core body temperature may be used to detect changes in body temperature indicative of disease states. Similarly, a sensor for detecting a particular analyte (e.g., a biomarker for inflammation, such as a cytokine and/or memory T cells, as just described) may be included. Alternatively or additionally, the implant may receive information (or a charger/controller coupled or coupleable to the implant) on the subject's physical parameters (e.g., heart rate, subjective/reported wellbeing, etc.) from an external database that may be used in a one-time or ongoing manner to adjust, increase, decrease, stop, start, or otherwise modify an applied treatment regime by the implant.
In particular, described herein are implants including at least a motion sensor such as an accelerometer. The accelerometer may be incorporated within the implant and/or the implant (or a controller affiliated with the implant) may receive information from a motion sensor (e.g., accelerometer) that is worn and/or implanted in the subject. For example, motion information or other wellbeing data from a wearable electronic device (e.g., Fitbit, etc.) may be provided to the implant and/or controller and used to modify one or more treatment parameter. Treatment parameters include dosing parameters such as frequency, amplitude, duty cycle, etc. as described above.
For example, in patients suffering from rheumatoid arthritis (RA), it has been observed that during flare-ups of RA, the patient typically exhibits less overall body motion, potentially due to pain in the joints. Therefore, a low amount of physical activity may indicate an increased need for treatment due to the presence of inflammation. Thus motion sensing may be used to increase/decrease applied therapy by the VNS (e.g., using a microstimulator as described herein).
If an accelerometer is included, it may be uniaxial, triaxial, or the like. As mentioned, the accelerometer can be located within the implant, or can be worn separately on another part of the body such as the arms, legs, torso, or wrist, for example. If the accelerometer is separate from the microstimulator, then the accelerometer can include wireless communications, such as Bluetooth, in order to transmit the data to the implant (microstimulator), and/or charger, and/or a prescription pad. In some embodiments, this data is transmitted to an external database, which may include data from a large population of patients. The transmitted data can include the stimulation parameters and protocol used and patient information and characteristics when the physical activity was measured. In some embodiments, a physical activity index can be generated for a patient. The index can be normalized to an activity level at time zero, or an activity level when the patient feels that the inflammation is well controlled, or an activity level when the patient feels that the inflammation is not being well controlled. In some embodiments, the physical activity index may be a combination of the patient's data and data from an external database that represents a compilation of the data from a larger patient population. In some embodiments, the physical activity index can be generated solely from the external database. In some embodiments, by comparing the measured activity level to the physical activity index, the system can determine whether the inflammation is getting better or worse or staying the same. In some embodiments, the data from the accelerometer can be used to generate a physical activity score. In some embodiments, the physical activity level can be correlated to the level of inflammation suffered by the patient. More generally, in some embodiments, the physical activity level can be used to determine a disease state. In other embodiments, the physical activity level can be used directly by itself without any correlation to disease state.
VNS can be modulated based on the physical activity measured by the accelerometer. For example, a decrease in physical activity can result in a modification of one or more stimulations parameters, such as more frequent stimulations (e.g. from once a day stimulation to twice a day stimulation), higher intensity/amplitude stimulations, and/or longer duration stimulations. In some embodiments, these adjusted stimulation parameters may be temporary or last for a predetermined duration, such as for up to 1, 2, 3, 4, 5, 6, 7, 14, 21, 30, 60, or 90 days, after which the system reverts back to the default stimulation parameters in order to avoid habituation. If the physical activity decreases again as a result of the reversion back to default stimulation parameters, the stimulation parameters can be adjusted as described above, and the default stimulation parameters may be updated to the adjusted parameters.
In some embodiments, a sensor can be used to measure heart rate (HR) and heart rate variability (HRV). As mentioned above, the HR/HRV sensor(s) may be integrated into the implant and/or separate from the implant. For example, an accelerometer worn on the torso over the heart may be able to detect the beating of the heart. In some embodiments, the accelerometer within the microstimulator can be used to detect the heart beat. Alternatively, the electrodes of the microstimulator and/or POD can be used to detect and measure electrical activity from the heart in order to measure heart rate and heart rate variability. For example, the stimulating electrodes of the microstimulator, when not delivering a stimulation, can be used to detect and measure electrical activity, such as an electrocardiogram do determine heart rate and HRV. In some embodiments, the heart rate data can be averaged over a period of time, such as hourly or daily, to generate a physical activity score, or help form the physical activity score along with the accelerometer data. In some embodiments, heart rate variability can be used to modulate stimulation parameters. In some embodiments, the heart rate variability can be correlated with physical activity or directly with the level of inflammation, or more generally, with the disease state. In some embodiments, both the heart rate variability and physical activity are inversely correlated with the level of inflammation. In other words, high levels of inflammation may be correlated with low levels of physical activity and low levels of heart rate variability. As described above for modulation of stimulation parameters based on physical activity, heart rate and/or heart rate variability can similarly be used to modulate stimulation parameters. For example, a decrease in average heart rate and/or a decrease in heart rate variability can result in a modification of one or more stimulations parameters, such as more frequent stimulations (e.g. from once a day stimulation to twice a day stimulation), higher intensity/amplitude stimulations, and/or longer duration stimulations.
In some variations, it may be particularly beneficial to detect a parameter, such as heart rate and/or HRV, using the same electrodes that are used to apply the VNS. Although these electrodes are typically held in communication with the vagus nerve, the inventors have found a signal corresponding to ECG signal may be determined by measuring electrical activity across the bipolar electrodes within the cuff, as shown in
A similar result was found for a cuff holding a bipolar cuff electrode (microstimulator) in a rat, as shown in
In general, heart rate variability (HRV) may provide an indicator of therapy efficacy, as it may effect vagal tone. For example, HRV may change as therapy is applied, as shown in
In some embodiments, HR and/or HRV can be determined before stimulation, during stimulation, and after stimulation. This allows the system and device to determine how the stimulation is affecting heart rate and/or HRV, and can also function as a safety mechanism. For example, in some embodiments, stimulation can be delayed or cancelled or aborted while in progress when the HR and/or HRV is above or below a predetermined threshold. In some embodiments, the predetermined thresholds can be determined based on a patient's normal resting HR and HRV, or a patient's sleeping HR and HRV if stimulation is applied when the patient is asleep. For example, the predetermined threshold can be about +/−10%, 20%, 30%, 40%, or 50% of the resting or sleeping HR and HRV. In some embodiments, the device and system can determine whether the stimulation is adversely affecting the patient's HR and/or HRV by comparing the HR and/or HRV from before, during, and after stimulation. If the stimulation is adversely affecting the HR and/or HRV, stimulation parameters can be adjusted, such as decreasing amplitude and/or duration and/or frequency of dosages, and/or the position of the implant on the vagus nerve can be adjusted.
In some embodiments, the microstimulator can be programmed to utilize the measured sensor data directly to modulate the stimulation parameters in a closed-loop implementation, as described above. In other embodiments, the sensor data, along with patient data including the status of the disease, such as inflammation, and the stimulation parameters and protocol, can be sent to the database stored on a computing device. The database and computing device can be server and/or part of a cloud computing network. For example, the data can be stored temporarily on the microstimulator, and can be periodically uploaded to the charger and/or prescription pad, and then transmitted to the external database. The external database can store data from a large population of patients using the same neurostimulation device to treat the same disease. From this collection of data, the server can compare the patient's stimulation parameters and protocol with patients sharing the same or similar characteristics, such as the same implant, the same disease (e.g., rheumatoid arthritis), and a similar response to VNS. The stimulation parameters can then be adjusted to match or be based on the stimulation parameters that were found to be successful in the similar group of patients. The server can then transmit these updated stimulation parameters to the microstimulator via the charger/prescription pad. In some embodiments, adjusting the stimulation parameters using the server with the external database can be combined with the closed-loop control of the microstimulator. For example, the server can be queried on a periodic basis, such as weekly, monthly, or quarterly, or on demand, to update the stimulation parameters, while the closed-loop control can remain active on an ongoing basis. In some embodiments, the data can be transmitted to a local computing device, such as the prescription pad, which can determine the modulation of the stimulation parameters. In some embodiments, the local computer may have a model database of patient parameters, disease state, and patient info that can be used to adjust the stimulation parameters. The model database can be updated on a regular basis, such as annually, semi-annually, or quarterly, for example.
User Interface for Implanted Neurostimulator
Also described herein are systems, including user interfaces for such systems, for user interaction with an implanted neurostimulator. The control software (including user interfaces) described herein may be used as part of any VNS apparatus, including, but not limited to, those described herein. In particular, described herein are apparatuses including a user interface for dynamic control of dose delivery of an implanted VNS microstimulator, such as those described herein. The dynamic control may provide an alert prior to delivery of a dose from an implanted microstimulator, and may present the user with a large, easy to read countdown of the time before the next dose, and permit the user to delay/postpone or cancel the scheduled dose. The user interface may illustrate in a timeline-like manner (showing night/day, hours, etc.) a graphic illustrating scheduled doses, and may allow the user to select a scheduled dose for delay or cancellation. In particular, the user interface may allow a user to select (using a control such as a slider, button, knob, etc.) a time period for delaying a dose within a predetermined time range (e.g., between 0.1 to 10 hour, etc.).
Any of the methods and user interfaces described herein may be implemented as software, hardware or firmware, and may be described as a non-transitory computer-readable storage medium storing a set of instructions capable of being executed by a processor (e.g., computer, tablet, smartphone, etc.), that when executed by the processor causes the processor to control perform any of the steps, including but not limited to: displaying, communicating with the user/patient, analyzing, modifying stimulation parameters (including timing, frequency, intensity, etc.), determining, alerting, or the like.
The user interface may also present the user with a display during the delivery of a dose, and may include a large control (e.g., button, virtual button, switch, etc.) to stop or abort a delivered dose. The button may be between 10 and 50% the display size, and may be configured to attract the user's attention (by flashing, bright color, etc.).
Thus, described herein are systems, including user interfaces for such systems, for user interaction with an implanted neurostimulator. The implanted neurostimulator may in particular be a vagus nerve stimulation (VNS) apparatus as incorporated herein by reference.
In any of these systems, the system may be software, firmware and/or hardware including a user interface for displaying and allowing user interactivity, where the user is the patient into which the neurostimulator has been implanted. The system may confirm that the user has an implanted neurostimulator, and may include safety and/or encryption to prevent improper modification of implant parameters and/or receipt of implant data. Proximity detection (e.g., detecting a specific implant that has been paired with the system) may be used, e.g., by receiving wireless information (Bluetooth, etc.) from the implant. The system may communicate directly or indirectly with the implant, including through a charger or control system.
Any of the user interfaces described herein may be configured to enhance and encourage user treatment (accepting dosage delivered) and compliance by ‘gamification’ of the dosing via the user interface. For example,
In any of the apparatuses described herein, the apparatus (e.g., including control software/user interface) may provide notices/notifications prior to dose delivery. For example, in some variations the apparatus may transmit a reminder (interrupt, push notification, etc.) prior to delivery of a dose at a predetermined time (e.g., 1 minute, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 60 minutes, etc.), and/or may display a countdown, as illustrated above. Thus, the apparatus may offers reminders (without stimulation) when a dose is about to occur and/or permit rescheduling or cancelling of a dose. The apparatus may provide an alert for other conditions (e.g., need to charge MR or energizer, need to time sync because of time zone change, etc.) in addition or instead of pre-dose alerts.
In any of the variations described herein, the apparatus may provide for editing (e.g., ‘next dose editing’) of any of the scheduled doses, as illustrated in
Although the examples shown above are shown as configured to use on a smartphone, or pad, they may alternatively or additionally be configured to operate on a wearable electronic device, such as a watch (e.g., smartwatch, etc.), as shown in
When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.
Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.
Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.
Although the terms “first” and “second” may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” means various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.
In general, any of the apparatuses and methods described herein should be understood to be inclusive, but all or a sub-set of the components and/or steps may alternatively be exclusive, and may be expressed as “consisting of” or alternatively “consisting essentially of” the various components, steps, sub-components or sub-steps.
As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word “about” or “approximately,” even if the term does not expressly appear. The phrase “about” or “approximately” may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/−0.1% of the stated value (or range of values), +/−1% of the stated value (or range of values), +/−2% of the stated value (or range of values), +/−5% of the stated value (or range of values), +/−10% of the stated value (or range of values), etc. Any numerical values given herein should also be understood to include about or approximately that value, unless the context indicates otherwise. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Any numerical range recited herein is intended to include all sub-ranges subsumed therein. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “X” is disclosed the “less than or equal to X” as well as “greater than or equal to X” (e.g., where X is a numerical value) is also disclosed. It is also understood that the throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point “15” are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
Although various illustrative embodiments are described above, any of a number of changes may be made to various embodiments without departing from the scope of the invention as described by the claims. For example, the order in which various described method steps are performed may often be changed in alternative embodiments, and in other alternative embodiments one or more method steps may be skipped altogether. Optional features of various device and system embodiments may be included in some embodiments and not in others. Therefore, the foregoing description is provided primarily for exemplary purposes and should not be interpreted to limit the scope of the invention as it is set forth in the claims.
The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. As mentioned, other embodiments may be utilized and derived there from, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure. Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term “invention” merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is, in fact, disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art upon reviewing the above description.
This application is a continuation of U.S. patent application Ser. No. 15/411,933, filed Jan. 20, 2017, titled “CONTROL OF VAGAL STIMULATION,” now U.S. Pat. No. 10,695,569, which claims priority to U.S. Provisional Patent Application No. 62/281,135, titled “SYSTEMS AND METHODS FOR MODULATING T-REGULATORY CELLS USING VAGUS NERVE STIMULATION”, filed on Jan. 20, 2016; U.S. Provisional Patent Application No. 62/286,950, titled “USER INTERFACE FOR IMPLANTED NEUROSTIMULATOR”, filed on Jan. 25, 2016; U.S. Provisional Patent Application No. 62/286,957, titled “ADAPTIVE CLOSED-LOOP CONTROL OF VAGAL STIMULATION”, filed on Jan. 25, 2016; and U.S. Provisional Patent Application No. 62/340,950, titled “ADAPTIVE CLOSED-LOOP CONTROL OF VAGAL STIMULATION”, filed on May 24, 2016. Each of these applications is herein incorporated by reference in its entirety. This application may also be related to one or more of: U.S. patent application Ser. No. 14/887,192, titled “NEURAL STIMULATION DEVICES AND SYSTEMS FOR TREATMENT OF CHRONIC INFLAMMATION”, filed on Oct. 19, 2015, Publication No. US-2016-0038745-A1; U.S. patent application Ser. No. 14/931,711, titled, “NERVE CUFF WITH POCKET FOR LEADLESS STIMULATOR”, filed on Nov. 3, 2015, Publication No. US-2016-0051813-A1; U.S. patent application Ser. No. 14/968,702, titled, “SINGLE-PULSE ACTIVATION OF THE CHOLINERGIC ANTI-INFLAMMATORY PATHWAY TO TREAT CHRONIC INFLAMMATION”, filed on Dec. 14, 2015, Publication No. US-2016-0096017-A1; U.S. patent application Ser. No. 13/338,185, titled “MODULATION OF SIRTUINS BY VAGUS NERVE STIMULATION”, filed on Dec. 27, 2011, Publication No. US-2013-0079834-A1; and U.S. patent application Ser. No. 14/782,715, titled “CLOSED-LOOP VAGUS NERVE STIMULATION”, filed on Oct. 6, 2015, Publication No. US-2016-0067497-A1. Each of these patent applications is herein incorporated by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2164121 | Pescador | Jun 1939 | A |
| 3363623 | Atwell | Jan 1968 | A |
| 3631534 | Hirota et al. | Dec 1971 | A |
| 4073296 | McCall | Feb 1978 | A |
| 4098277 | Mendell | Jul 1978 | A |
| 4305402 | Katims | Dec 1981 | A |
| 4503863 | Katims | Mar 1985 | A |
| 4573481 | Bullara | Mar 1986 | A |
| 4590946 | Loeb | May 1986 | A |
| 4632095 | Libin | Dec 1986 | A |
| 4649936 | Ungar et al. | Mar 1987 | A |
| 4702254 | Zabara | Oct 1987 | A |
| 4840793 | Todd, III et al. | Jun 1989 | A |
| 4867164 | Zabara | Sep 1989 | A |
| 4929734 | Coughenour et al. | May 1990 | A |
| 4930516 | Alfano et al. | Jun 1990 | A |
| 4935234 | Todd, III et al. | Jun 1990 | A |
| 4979511 | Terry, Jr. | Dec 1990 | A |
| 4991578 | Cohen | Feb 1991 | A |
| 5019648 | Schlossman et al. | May 1991 | A |
| 5025807 | Zabara | Jun 1991 | A |
| 5038781 | Lynch | Aug 1991 | A |
| 5049659 | Cantor et al. | Sep 1991 | A |
| 5073560 | Wu et al. | Dec 1991 | A |
| 5106853 | Showell et al. | Apr 1992 | A |
| 5111815 | Mower | May 1992 | A |
| 5154172 | Terry, Jr. et al. | Oct 1992 | A |
| 5175166 | Dunbar et al. | Dec 1992 | A |
| 5179950 | Stanislaw | Jan 1993 | A |
| 5186170 | Varrichio et al. | Feb 1993 | A |
| 5188104 | Wernicke et al. | Feb 1993 | A |
| 5203326 | Collins | Apr 1993 | A |
| 5205285 | Baker, Jr. | Apr 1993 | A |
| 5215086 | Terry, Jr. et al. | Jun 1993 | A |
| 5215089 | Baker, Jr. | Jun 1993 | A |
| 5222494 | Baker, Jr. | Jun 1993 | A |
| 5231988 | Wernicke et al. | Aug 1993 | A |
| 5235980 | Varrichio et al. | Aug 1993 | A |
| 5237991 | Baker et al. | Aug 1993 | A |
| 5251634 | Weinberg | Oct 1993 | A |
| 5263480 | Wernicke et al. | Nov 1993 | A |
| 5269303 | Wernicke et al. | Dec 1993 | A |
| 5299569 | Wernicke et al. | Apr 1994 | A |
| 5304206 | Baker, Jr. et al. | Apr 1994 | A |
| 5330507 | Schwartz | Jul 1994 | A |
| 5330515 | Rutecki et al. | Jul 1994 | A |
| 5335657 | Terry, Jr. et al. | Aug 1994 | A |
| 5344438 | Testerman et al. | Sep 1994 | A |
| 5351394 | Weinberg | Oct 1994 | A |
| 5403845 | Dunbar et al. | Apr 1995 | A |
| 5458625 | Kendall | Oct 1995 | A |
| 5472841 | Jayasena et al. | Dec 1995 | A |
| 5487756 | Kallesoe et al. | Jan 1996 | A |
| 5496938 | Gold et al. | Mar 1996 | A |
| 5503978 | Schneider et al. | Apr 1996 | A |
| 5531778 | Maschino et al. | Jul 1996 | A |
| 5540730 | Terry, Jr. et al. | Jul 1996 | A |
| 5540734 | Zabara | Jul 1996 | A |
| 5567588 | Gold et al. | Oct 1996 | A |
| 5567724 | Kelleher et al. | Oct 1996 | A |
| 5571150 | Wernicke et al. | Nov 1996 | A |
| 5580737 | Polisky et al. | Dec 1996 | A |
| 5582981 | Toole et al. | Dec 1996 | A |
| 5604231 | Smith et al. | Feb 1997 | A |
| 5607459 | Paul et al. | Mar 1997 | A |
| 5611350 | John | Mar 1997 | A |
| 5618818 | Ojo et al. | Apr 1997 | A |
| 5629285 | Black et al. | May 1997 | A |
| 5637459 | Burke et al. | Jun 1997 | A |
| 5651378 | Matheny et al. | Jul 1997 | A |
| 5654151 | Allen et al. | Aug 1997 | A |
| 5683867 | Biesecker et al. | Nov 1997 | A |
| 5690681 | Geddes et al. | Nov 1997 | A |
| 5700282 | Zabara | Dec 1997 | A |
| 5705337 | Gold et al. | Jan 1998 | A |
| 5707400 | Terry, Jr. et al. | Jan 1998 | A |
| 5709853 | Iino et al. | Jan 1998 | A |
| 5712375 | Jensen et al. | Jan 1998 | A |
| 5718912 | Thomspon et al. | Feb 1998 | A |
| 5726017 | Lochrie et al. | Mar 1998 | A |
| 5726179 | Messer, Jr. et al. | Mar 1998 | A |
| 5727556 | Weth et al. | Mar 1998 | A |
| 5733255 | Dinh et al. | Mar 1998 | A |
| 5741802 | Kem et al. | Apr 1998 | A |
| 5773598 | Burke et al. | Jun 1998 | A |
| 5786462 | Schneider et al. | Jul 1998 | A |
| 5788656 | Mino | Aug 1998 | A |
| 5792210 | Wamubu et al. | Aug 1998 | A |
| 5824027 | Hoffer et al. | Oct 1998 | A |
| 5853005 | Scanlon | Dec 1998 | A |
| 5854289 | Bianchi et al. | Dec 1998 | A |
| 5902814 | Gordon et al. | May 1999 | A |
| 5913876 | Taylor et al. | Jun 1999 | A |
| 5916239 | Geddes et al. | Jun 1999 | A |
| 5919216 | Houben et al. | Jul 1999 | A |
| 5928272 | Adkins et al. | Jul 1999 | A |
| 5964794 | Bolz et al. | Oct 1999 | A |
| 5977144 | Meyer et al. | Nov 1999 | A |
| 5994330 | El Khoury | Nov 1999 | A |
| 6002964 | Feler et al. | Dec 1999 | A |
| 6006134 | Hill et al. | Dec 1999 | A |
| 6017891 | Eibl et al. | Jan 2000 | A |
| 6028186 | Tasset et al. | Feb 2000 | A |
| 6051017 | Loeb et al. | Apr 2000 | A |
| 6083696 | Biesecker et al. | Jul 2000 | A |
| 6083905 | Voorberg et al. | Jul 2000 | A |
| 6096728 | Collins et al. | Aug 2000 | A |
| 6104956 | Naritoku et al. | Aug 2000 | A |
| 6110900 | Gold et al. | Aug 2000 | A |
| 6110914 | Phillips et al. | Aug 2000 | A |
| 6117837 | Tracey et al. | Sep 2000 | A |
| 6124449 | Gold et al. | Sep 2000 | A |
| 6127119 | Stephens et al. | Oct 2000 | A |
| 6140490 | Biesecker et al. | Oct 2000 | A |
| 6141590 | Renirie et al. | Oct 2000 | A |
| 6147204 | Gold et al. | Nov 2000 | A |
| 6159145 | Satoh | Dec 2000 | A |
| 6164284 | Schulman et al. | Dec 2000 | A |
| 6166048 | Bencherif | Dec 2000 | A |
| 6168778 | Janjic et al. | Jan 2001 | B1 |
| 6171795 | Korman et al. | Jan 2001 | B1 |
| 6205359 | Boveja | Mar 2001 | B1 |
| 6208894 | Schulman et al. | Mar 2001 | B1 |
| 6208902 | Boveja | Mar 2001 | B1 |
| 6210321 | Di Mino et al. | Apr 2001 | B1 |
| 6224862 | Turecek et al. | May 2001 | B1 |
| 6233488 | Hess | May 2001 | B1 |
| 6266564 | Hill et al. | Jul 2001 | B1 |
| 6269270 | Boveja | Jul 2001 | B1 |
| 6304775 | Iasemidis et al. | Oct 2001 | B1 |
| 6308104 | Taylor et al. | Oct 2001 | B1 |
| 6337997 | Rise | Jan 2002 | B1 |
| 6339725 | Naritoku et al. | Jan 2002 | B1 |
| 6341236 | Osorio et al. | Jan 2002 | B1 |
| 6356787 | Rezai | Mar 2002 | B1 |
| 6356788 | Boveja | Mar 2002 | B2 |
| 6381499 | Taylor et al. | Apr 2002 | B1 |
| 6405732 | Edwards et al. | Jun 2002 | B1 |
| 6407095 | Lochead et al. | Jun 2002 | B1 |
| 6428484 | Battmer et al. | Aug 2002 | B1 |
| 6429217 | Puskas | Aug 2002 | B1 |
| 6447443 | Keogh et al. | Sep 2002 | B1 |
| 6449507 | Hill et al. | Sep 2002 | B1 |
| 6473644 | Terry, Jr. et al. | Oct 2002 | B1 |
| 6479523 | Puskas | Nov 2002 | B1 |
| 6487446 | Hill et al. | Nov 2002 | B1 |
| 6511500 | Rahme | Jan 2003 | B1 |
| 6528529 | Brann et al. | Mar 2003 | B1 |
| 6532388 | Hill et al. | Mar 2003 | B1 |
| 6542774 | Hill et al. | Apr 2003 | B2 |
| 6556868 | Naritoku et al. | Apr 2003 | B2 |
| 6564102 | Boveja | May 2003 | B1 |
| 6587719 | Barrett et al. | Jul 2003 | B1 |
| 6587727 | Osorio et al. | Jul 2003 | B2 |
| 6600956 | Maschino et al. | Jul 2003 | B2 |
| 6602891 | Messer et al. | Aug 2003 | B2 |
| 6609025 | Barrett et al. | Aug 2003 | B2 |
| 6610713 | Tracey | Aug 2003 | B2 |
| 6611715 | Boveja | Aug 2003 | B1 |
| 6615081 | Boveja | Sep 2003 | B1 |
| 6615085 | Boveja | Sep 2003 | B1 |
| 6622038 | Barrett | Sep 2003 | B2 |
| 6622041 | Terry, Jr. et al. | Sep 2003 | B2 |
| 6622047 | Barrett et al. | Sep 2003 | B2 |
| 6628987 | Hill et al. | Sep 2003 | B1 |
| 6633779 | Schuler et al. | Oct 2003 | B1 |
| 6656960 | Puskas | Dec 2003 | B2 |
| 6668191 | Boveja | Dec 2003 | B1 |
| 6671556 | Osorio et al. | Dec 2003 | B2 |
| 6684105 | Cohen et al. | Jan 2004 | B2 |
| 6690973 | Hill et al. | Feb 2004 | B2 |
| 6718208 | Hill et al. | Apr 2004 | B2 |
| 6721603 | Zabara et al. | Apr 2004 | B2 |
| 6735471 | Hill et al. | May 2004 | B2 |
| 6735475 | Whitehurst et al. | May 2004 | B1 |
| 6760626 | Boveja | Jul 2004 | B1 |
| 6778854 | Puskas | Aug 2004 | B2 |
| 6804558 | Haller et al. | Oct 2004 | B2 |
| RE38654 | Hill et al. | Nov 2004 | E |
| 6826428 | Chen et al. | Nov 2004 | B1 |
| 6832114 | Whitehurst et al. | Dec 2004 | B1 |
| 6838471 | Tracey | Jan 2005 | B2 |
| RE38705 | Hill et al. | Feb 2005 | E |
| 6879859 | Boveja | Apr 2005 | B1 |
| 6885888 | Rezai | Apr 2005 | B2 |
| 6901294 | Whitehurst et al. | May 2005 | B1 |
| 6904318 | Hill et al. | Jun 2005 | B2 |
| 6920357 | Osorio et al. | Jul 2005 | B2 |
| 6928320 | King | Aug 2005 | B2 |
| 6934583 | Weinberg et al. | Aug 2005 | B2 |
| 6937903 | Schuler et al. | Aug 2005 | B2 |
| 6961618 | Osorio et al. | Nov 2005 | B2 |
| 6978787 | Broniatowski | Dec 2005 | B1 |
| 7011638 | Schuler et al. | Mar 2006 | B2 |
| 7054686 | MacDonald | May 2006 | B2 |
| 7054692 | Whitehurst et al. | May 2006 | B1 |
| 7058447 | Hill et al. | Jun 2006 | B2 |
| 7062320 | Ehlinger, Jr. | Jun 2006 | B2 |
| 7069082 | Lindenthaler | Jun 2006 | B2 |
| 7072720 | Puskas | Jul 2006 | B2 |
| 7076307 | Boveja et al. | Jul 2006 | B2 |
| 7142910 | Puskas | Nov 2006 | B2 |
| 7142917 | Fukui | Nov 2006 | B2 |
| 7149574 | Yun et al. | Dec 2006 | B2 |
| 7155279 | Whitehurst et al. | Dec 2006 | B2 |
| 7155284 | Whitehurst et al. | Dec 2006 | B1 |
| 7167750 | Knudson et al. | Jan 2007 | B2 |
| 7167751 | Whitehurst et al. | Jan 2007 | B1 |
| 7174218 | Kuzma | Feb 2007 | B1 |
| 7184828 | Hill et al. | Feb 2007 | B2 |
| 7184829 | Hill et al. | Feb 2007 | B2 |
| 7191012 | Boveja et al. | Mar 2007 | B2 |
| 7204815 | Connor | Apr 2007 | B2 |
| 7209787 | DiLorenzo | Apr 2007 | B2 |
| 7225019 | Jahns et al. | May 2007 | B2 |
| 7228167 | Kara et al. | Jun 2007 | B2 |
| 7238715 | Tracey et al. | Jul 2007 | B2 |
| 7242984 | DiLorenzo | Jul 2007 | B2 |
| 7269457 | Shafer et al. | Sep 2007 | B2 |
| 7345178 | Nunes et al. | Mar 2008 | B2 |
| 7373204 | Gelfand et al. | May 2008 | B2 |
| 7389145 | Kilgore et al. | Jun 2008 | B2 |
| 7454245 | Armstrong et al. | Nov 2008 | B2 |
| 7467016 | Colborn | Dec 2008 | B2 |
| 7544497 | Sinclair et al. | Jun 2009 | B2 |
| 7561918 | Armstrong et al. | Jul 2009 | B2 |
| 7711432 | Thimineur et al. | May 2010 | B2 |
| 7729760 | Patel et al. | Jun 2010 | B2 |
| 7751891 | Armstrong et al. | Jul 2010 | B2 |
| 7776326 | Milbrandt et al. | Aug 2010 | B2 |
| 7797058 | Mrva et al. | Sep 2010 | B2 |
| 7819883 | Westfund et al. | Oct 2010 | B2 |
| 7822486 | Foster et al. | Oct 2010 | B2 |
| 7829556 | Bemis et al. | Nov 2010 | B2 |
| 7869885 | Begnaud et al. | Jan 2011 | B2 |
| 7937145 | Dobak | May 2011 | B2 |
| 7962220 | Kolafa et al. | Jun 2011 | B2 |
| 7974701 | Armstrong | Jul 2011 | B2 |
| 7974707 | Inman | Jul 2011 | B2 |
| 7996088 | Marrosu et al. | Aug 2011 | B2 |
| 7996092 | Mrva et al. | Aug 2011 | B2 |
| 8019419 | Panescu et al. | Sep 2011 | B1 |
| 8060208 | Kilgore et al. | Nov 2011 | B2 |
| 8103349 | Donders et al. | Jan 2012 | B2 |
| 8165668 | Dacey, Jr. et al. | Apr 2012 | B2 |
| 8180446 | Dacey, Jr. et al. | May 2012 | B2 |
| 8180447 | Dacey et al. | May 2012 | B2 |
| 8195287 | Dacey, Jr. et al. | Jun 2012 | B2 |
| 8214056 | Hoffer et al. | Jul 2012 | B2 |
| 8233982 | Libbus | Jul 2012 | B2 |
| 8391970 | Tracey et al. | Mar 2013 | B2 |
| 8412338 | Faltys | Apr 2013 | B2 |
| 8571654 | Libbus et al. | Oct 2013 | B2 |
| 8577458 | Libbus et al. | Nov 2013 | B1 |
| 8600505 | Libbus et al. | Dec 2013 | B2 |
| 8612002 | Faltys et al. | Dec 2013 | B2 |
| 8630709 | Libbus et al. | Jan 2014 | B2 |
| 8688212 | Libbus et al. | Apr 2014 | B2 |
| 8700150 | Libbus et al. | Apr 2014 | B2 |
| 8729129 | Tracey et al. | May 2014 | B2 |
| 8788034 | Levine et al. | Jul 2014 | B2 |
| 8843210 | Simon et al. | Sep 2014 | B2 |
| 8855767 | Faltys et al. | Oct 2014 | B2 |
| 8886339 | Faltys et al. | Nov 2014 | B2 |
| 8914114 | Tracey et al. | Dec 2014 | B2 |
| 8918178 | Simon et al. | Dec 2014 | B2 |
| 8918191 | Libbus et al. | Dec 2014 | B2 |
| 8923964 | Libbus et al. | Dec 2014 | B2 |
| 8983628 | Simon et al. | Mar 2015 | B2 |
| 8983629 | Simon et al. | Mar 2015 | B2 |
| 8996116 | Faltys et al. | Mar 2015 | B2 |
| 9114262 | Libbus et al. | Aug 2015 | B2 |
| 9162064 | Faltys et al. | Oct 2015 | B2 |
| 9174041 | Faltys et al. | Nov 2015 | B2 |
| 9211409 | Tracey et al. | Dec 2015 | B2 |
| 9211410 | Levine et al. | Dec 2015 | B2 |
| 9254383 | Simon et al. | Feb 2016 | B2 |
| 9272143 | Libbus et al. | Mar 2016 | B2 |
| 9358381 | Simon et al. | Jun 2016 | B2 |
| 9399134 | Simon et al. | Jul 2016 | B2 |
| 9403001 | Simon et al. | Aug 2016 | B2 |
| 9409024 | KenKnight et al. | Aug 2016 | B2 |
| 9415224 | Libbus et al. | Aug 2016 | B2 |
| 9452290 | Libbus et al. | Sep 2016 | B2 |
| 9504832 | Libbus et al. | Nov 2016 | B2 |
| 9511228 | Amurthur et al. | Dec 2016 | B2 |
| 9533153 | Libbus et al. | Jan 2017 | B2 |
| 9572983 | Levine et al. | Feb 2017 | B2 |
| 9662490 | Tracey et al. | May 2017 | B2 |
| 9700716 | Faltys et al. | Jul 2017 | B2 |
| 9833621 | Levine | Dec 2017 | B2 |
| 9849286 | Levine et al. | Dec 2017 | B2 |
| 9987492 | Tracey et al. | Jun 2018 | B2 |
| 9993651 | Faltys et al. | Jun 2018 | B2 |
| 10166395 | Tracey et al. | Jan 2019 | B2 |
| 10220203 | Faltys et al. | Mar 2019 | B2 |
| 10449358 | Levine et al. | Oct 2019 | B2 |
| 10561846 | Tracey et al. | Feb 2020 | B2 |
| 10583304 | Faltys et al. | Mar 2020 | B2 |
| 10596367 | Faltys et al. | Mar 2020 | B2 |
| 10695569 | Levine et al. | Jun 2020 | B2 |
| 10716936 | Faltys et al. | Jul 2020 | B2 |
| 20010002441 | Boveja | May 2001 | A1 |
| 20010034542 | Mann | Oct 2001 | A1 |
| 20020026141 | Houben | Feb 2002 | A1 |
| 20020040035 | Myers et al. | Apr 2002 | A1 |
| 20020077675 | Greenstein | Jun 2002 | A1 |
| 20020086871 | O'Neill et al. | Jul 2002 | A1 |
| 20020095139 | Keogh et al. | Jul 2002 | A1 |
| 20020099417 | Naritoku et al. | Jul 2002 | A1 |
| 20020138075 | Edwards et al. | Sep 2002 | A1 |
| 20020138109 | Keogh et al. | Sep 2002 | A1 |
| 20020193859 | Schulman et al. | Dec 2002 | A1 |
| 20020198570 | Puskas | Dec 2002 | A1 |
| 20030018367 | DiLorenzo | Jan 2003 | A1 |
| 20030032852 | Perreault et al. | Feb 2003 | A1 |
| 20030045909 | Gross et al. | Mar 2003 | A1 |
| 20030088301 | King | May 2003 | A1 |
| 20030191404 | Klein | Oct 2003 | A1 |
| 20030194752 | Anderson et al. | Oct 2003 | A1 |
| 20030195578 | Perron et al. | Oct 2003 | A1 |
| 20030212440 | Boveja | Nov 2003 | A1 |
| 20030229380 | Adams et al. | Dec 2003 | A1 |
| 20030236557 | Whitehurst et al. | Dec 2003 | A1 |
| 20030236558 | Whitehurst et al. | Dec 2003 | A1 |
| 20040002546 | Altschuler | Jan 2004 | A1 |
| 20040015202 | Chandler et al. | Jan 2004 | A1 |
| 20040015204 | Whitehurst et al. | Jan 2004 | A1 |
| 20040015205 | Whitehurst et al. | Jan 2004 | A1 |
| 20040024422 | Hill et al. | Feb 2004 | A1 |
| 20040024428 | Barrett et al. | Feb 2004 | A1 |
| 20040024439 | Riso | Feb 2004 | A1 |
| 20040030362 | Hill et al. | Feb 2004 | A1 |
| 20040039427 | Barrett et al. | Feb 2004 | A1 |
| 20040048795 | Ivanova et al. | Mar 2004 | A1 |
| 20040049121 | Yaron | Mar 2004 | A1 |
| 20040049240 | Gerber et al. | Mar 2004 | A1 |
| 20040059383 | Puskas | Mar 2004 | A1 |
| 20040111139 | McCreery et al. | Jun 2004 | A1 |
| 20040138517 | Osorio et al. | Jul 2004 | A1 |
| 20040138518 | Rise et al. | Jul 2004 | A1 |
| 20040138536 | Frei et al. | Jul 2004 | A1 |
| 20040146949 | Tan et al. | Jul 2004 | A1 |
| 20040153127 | Gordon et al. | Aug 2004 | A1 |
| 20040158119 | Osorio et al. | Aug 2004 | A1 |
| 20040162584 | Hill et al. | Aug 2004 | A1 |
| 20040172074 | Yoshihito | Sep 2004 | A1 |
| 20040172085 | Knudson et al. | Sep 2004 | A1 |
| 20040172086 | Knudson et al. | Sep 2004 | A1 |
| 20040172088 | Knudson et al. | Sep 2004 | A1 |
| 20040172094 | Cohen et al. | Sep 2004 | A1 |
| 20040176812 | Knudson et al. | Sep 2004 | A1 |
| 20040178706 | D'Orso | Sep 2004 | A1 |
| 20040193231 | David et al. | Sep 2004 | A1 |
| 20040199209 | Hill et al. | Oct 2004 | A1 |
| 20040199210 | Shelchuk | Oct 2004 | A1 |
| 20040204355 | Tracey et al. | Oct 2004 | A1 |
| 20040215272 | Haubrich et al. | Oct 2004 | A1 |
| 20040215287 | Swoyer et al. | Oct 2004 | A1 |
| 20040236381 | Dinsmoor et al. | Nov 2004 | A1 |
| 20040236382 | Dinsmoor et al. | Nov 2004 | A1 |
| 20040240691 | Grafenberg | Dec 2004 | A1 |
| 20040243182 | Cohen et al. | Dec 2004 | A1 |
| 20040254612 | Ezra et al. | Dec 2004 | A1 |
| 20040267152 | Pineda | Dec 2004 | A1 |
| 20050021092 | Yun et al. | Jan 2005 | A1 |
| 20050021101 | Chen et al. | Jan 2005 | A1 |
| 20050027328 | Greenstein | Feb 2005 | A1 |
| 20050043774 | Devlin et al. | Feb 2005 | A1 |
| 20050049655 | Boveja et al. | Mar 2005 | A1 |
| 20050065553 | Ben Ezra et al. | Mar 2005 | A1 |
| 20050065573 | Rezai | Mar 2005 | A1 |
| 20050065575 | Dobak | Mar 2005 | A1 |
| 20050070970 | Knudson et al. | Mar 2005 | A1 |
| 20050070974 | Knudson et al. | Mar 2005 | A1 |
| 20050075701 | Shafer | Apr 2005 | A1 |
| 20050075702 | Shafer | Apr 2005 | A1 |
| 20050095246 | Shafer | May 2005 | A1 |
| 20050096707 | Hill et al. | May 2005 | A1 |
| 20050103351 | Stomberg et al. | May 2005 | A1 |
| 20050113894 | Zilberman et al. | May 2005 | A1 |
| 20050131467 | Boveja | Jun 2005 | A1 |
| 20050131486 | Boveja et al. | Jun 2005 | A1 |
| 20050131487 | Boveja | Jun 2005 | A1 |
| 20050131493 | Boveja et al. | Jun 2005 | A1 |
| 20050137644 | Boveja et al. | Jun 2005 | A1 |
| 20050137645 | Voipio et al. | Jun 2005 | A1 |
| 20050143781 | Carbunaru et al. | Jun 2005 | A1 |
| 20050143787 | Boveja et al. | Jun 2005 | A1 |
| 20050149126 | Libbus | Jul 2005 | A1 |
| 20050149129 | Libbus et al. | Jul 2005 | A1 |
| 20050149131 | Libbus et al. | Jul 2005 | A1 |
| 20050153885 | Yun et al. | Jul 2005 | A1 |
| 20050154425 | Boveja et al. | Jul 2005 | A1 |
| 20050154426 | Boveja et al. | Jul 2005 | A1 |
| 20050165458 | Boveja et al. | Jul 2005 | A1 |
| 20050177200 | George et al. | Aug 2005 | A1 |
| 20050182288 | Zabara | Aug 2005 | A1 |
| 20050182467 | Hunter et al. | Aug 2005 | A1 |
| 20050187584 | Denker et al. | Aug 2005 | A1 |
| 20050187586 | David et al. | Aug 2005 | A1 |
| 20050187590 | Boveja et al. | Aug 2005 | A1 |
| 20050191661 | Gatanaga et al. | Sep 2005 | A1 |
| 20050192644 | Boveja et al. | Sep 2005 | A1 |
| 20050197600 | Schuler et al. | Sep 2005 | A1 |
| 20050197675 | David et al. | Sep 2005 | A1 |
| 20050197678 | Boveja et al. | Sep 2005 | A1 |
| 20050203501 | Aldrich et al. | Sep 2005 | A1 |
| 20050209654 | Boveja et al. | Sep 2005 | A1 |
| 20050216064 | Heruth et al. | Sep 2005 | A1 |
| 20050216070 | Boveja et al. | Sep 2005 | A1 |
| 20050216071 | Devlin et al. | Sep 2005 | A1 |
| 20050240229 | Whitehurst et al. | Oct 2005 | A1 |
| 20050240231 | Aldrich et al. | Oct 2005 | A1 |
| 20050240241 | Yun et al. | Oct 2005 | A1 |
| 20050240242 | DiLorenzo | Oct 2005 | A1 |
| 20050251220 | Barrett et al. | Nov 2005 | A1 |
| 20050251222 | Barrett et al. | Nov 2005 | A1 |
| 20050267542 | David et al. | Dec 2005 | A1 |
| 20050267547 | Knudson et al. | Dec 2005 | A1 |
| 20050277912 | John | Dec 2005 | A1 |
| 20050283198 | Haubrich et al. | Dec 2005 | A1 |
| 20060009815 | Boveja et al. | Jan 2006 | A1 |
| 20060015151 | Aldrich | Jan 2006 | A1 |
| 20060025828 | Armstrong et al. | Feb 2006 | A1 |
| 20060036293 | Whitehurst et al. | Feb 2006 | A1 |
| 20060052657 | Zabara | Mar 2006 | A9 |
| 20060052831 | Fukui | Mar 2006 | A1 |
| 20060052836 | Kim et al. | Mar 2006 | A1 |
| 20060058851 | Cigaina | Mar 2006 | A1 |
| 20060064137 | Stone | Mar 2006 | A1 |
| 20060064139 | Chung et al. | Mar 2006 | A1 |
| 20060074450 | Boveja et al. | Apr 2006 | A1 |
| 20060074473 | Gertner | Apr 2006 | A1 |
| 20060079936 | Boveja et al. | Apr 2006 | A1 |
| 20060085046 | Rezai et al. | Apr 2006 | A1 |
| 20060095081 | Zhou et al. | May 2006 | A1 |
| 20060095090 | De Ridder | May 2006 | A1 |
| 20060100668 | Ben-David et al. | May 2006 | A1 |
| 20060106755 | Stuhec | May 2006 | A1 |
| 20060111644 | Guttag et al. | May 2006 | A1 |
| 20060111754 | Rezai et al. | May 2006 | A1 |
| 20060111755 | Stone et al. | May 2006 | A1 |
| 20060116739 | Betser et al. | Jun 2006 | A1 |
| 20060122675 | Libbus et al. | Jun 2006 | A1 |
| 20060129200 | Kurokawa | Jun 2006 | A1 |
| 20060129202 | Armstrong | Jun 2006 | A1 |
| 20060135998 | Libbus et al. | Jun 2006 | A1 |
| 20060136024 | Cohen et al. | Jun 2006 | A1 |
| 20060142802 | Armstrong | Jun 2006 | A1 |
| 20060142822 | Tulgar | Jun 2006 | A1 |
| 20060149337 | John | Jul 2006 | A1 |
| 20060155495 | Osorio et al. | Jul 2006 | A1 |
| 20060161216 | John et al. | Jul 2006 | A1 |
| 20060161217 | Jaax et al. | Jul 2006 | A1 |
| 20060167497 | Armstrong et al. | Jul 2006 | A1 |
| 20060167498 | DiLorenzo | Jul 2006 | A1 |
| 20060167501 | Ben-David et al. | Jul 2006 | A1 |
| 20060173493 | Armstrong et al. | Aug 2006 | A1 |
| 20060173508 | Stone et al. | Aug 2006 | A1 |
| 20060178691 | Binmoeller | Aug 2006 | A1 |
| 20060178703 | Huston et al. | Aug 2006 | A1 |
| 20060178706 | Lisogurski et al. | Aug 2006 | A1 |
| 20060190044 | Libbus et al. | Aug 2006 | A1 |
| 20060200208 | Terry, Jr. et al. | Sep 2006 | A1 |
| 20060200219 | Thrope et al. | Sep 2006 | A1 |
| 20060206155 | Ben-David et al. | Sep 2006 | A1 |
| 20060206158 | Wu et al. | Sep 2006 | A1 |
| 20060229677 | Moffitt et al. | Oct 2006 | A1 |
| 20060229681 | Fischell | Oct 2006 | A1 |
| 20060241697 | Libbus et al. | Oct 2006 | A1 |
| 20060241699 | Libbus et al. | Oct 2006 | A1 |
| 20060247719 | Maschino et al. | Nov 2006 | A1 |
| 20060247721 | Maschino et al. | Nov 2006 | A1 |
| 20060247722 | Maschino et al. | Nov 2006 | A1 |
| 20060259077 | Pardo et al. | Nov 2006 | A1 |
| 20060259084 | Zhang et al. | Nov 2006 | A1 |
| 20060259085 | Zhang et al. | Nov 2006 | A1 |
| 20060259107 | Caparso et al. | Nov 2006 | A1 |
| 20060271115 | Ben-Ezra et al. | Nov 2006 | A1 |
| 20060282121 | Payne et al. | Dec 2006 | A1 |
| 20060282131 | Caparso et al. | Dec 2006 | A1 |
| 20060282145 | Caparso et al. | Dec 2006 | A1 |
| 20060287678 | Shafer | Dec 2006 | A1 |
| 20060287679 | Stone | Dec 2006 | A1 |
| 20060292099 | Milburn et al. | Dec 2006 | A1 |
| 20060293720 | DiLorenzo | Dec 2006 | A1 |
| 20060293721 | Tarver et al. | Dec 2006 | A1 |
| 20060293723 | Whitehurst et al. | Dec 2006 | A1 |
| 20070016262 | Gross et al. | Jan 2007 | A1 |
| 20070016263 | Armstrong et al. | Jan 2007 | A1 |
| 20070021785 | Inman et al. | Jan 2007 | A1 |
| 20070021786 | Parnis et al. | Jan 2007 | A1 |
| 20070021814 | Inman et al. | Jan 2007 | A1 |
| 20070025608 | Armstrong | Feb 2007 | A1 |
| 20070027482 | Parnis et al. | Feb 2007 | A1 |
| 20070027483 | Maschino et al. | Feb 2007 | A1 |
| 20070027484 | Guzman et al. | Feb 2007 | A1 |
| 20070027486 | Armstrong | Feb 2007 | A1 |
| 20070027492 | Maschino et al. | Feb 2007 | A1 |
| 20070027496 | Parnis et al. | Feb 2007 | A1 |
| 20070027497 | Parnis | Feb 2007 | A1 |
| 20070027498 | Maschino et al. | Feb 2007 | A1 |
| 20070027499 | Maschino et al. | Feb 2007 | A1 |
| 20070027500 | Maschino et al. | Feb 2007 | A1 |
| 20070027504 | Barrett et al. | Feb 2007 | A1 |
| 20070055324 | Thompson et al. | Mar 2007 | A1 |
| 20070067004 | Boveja et al. | Mar 2007 | A1 |
| 20070083242 | Mazgalev et al. | Apr 2007 | A1 |
| 20070093434 | Rossetti et al. | Apr 2007 | A1 |
| 20070093870 | Maschino | Apr 2007 | A1 |
| 20070093875 | Chavan et al. | Apr 2007 | A1 |
| 20070100263 | Merfeld | May 2007 | A1 |
| 20070100377 | Armstrong et al. | May 2007 | A1 |
| 20070100378 | Maschino | May 2007 | A1 |
| 20070100380 | Fukui | May 2007 | A1 |
| 20070100392 | Maschino et al. | May 2007 | A1 |
| 20070106339 | Errico et al. | May 2007 | A1 |
| 20070112404 | Manti et al. | May 2007 | A1 |
| 20070118177 | Libbus et al. | May 2007 | A1 |
| 20070118178 | Fukui | May 2007 | A1 |
| 20070129767 | Wahlstrand | Jun 2007 | A1 |
| 20070129780 | Whiteharst et al. | Jun 2007 | A1 |
| 20070135846 | Knudson et al. | Jun 2007 | A1 |
| 20070135856 | Knudson et al. | Jun 2007 | A1 |
| 20070135857 | Knudson et al. | Jun 2007 | A1 |
| 20070135858 | Knudson et al. | Jun 2007 | A1 |
| 20070142870 | Knudson et al. | Jun 2007 | A1 |
| 20070142871 | Libbus et al. | Jun 2007 | A1 |
| 20070142874 | John | Jun 2007 | A1 |
| 20070150006 | Libbus et al. | Jun 2007 | A1 |
| 20070150011 | Meyer et al. | Jun 2007 | A1 |
| 20070150021 | Chen et al. | Jun 2007 | A1 |
| 20070150027 | Rogers | Jun 2007 | A1 |
| 20070156180 | Jaax et al. | Jul 2007 | A1 |
| 20070198063 | Hunter et al. | Aug 2007 | A1 |
| 20070239243 | Moffitt et al. | Oct 2007 | A1 |
| 20070244522 | Overstreet | Oct 2007 | A1 |
| 20070250145 | Kraus et al. | Oct 2007 | A1 |
| 20070255320 | Inman et al. | Nov 2007 | A1 |
| 20070255333 | Giftakis | Nov 2007 | A1 |
| 20070255339 | Torgerson | Nov 2007 | A1 |
| 20080021517 | Dietrich | Jan 2008 | A1 |
| 20080021520 | Dietrich | Jan 2008 | A1 |
| 20080046055 | Durand et al. | Feb 2008 | A1 |
| 20080051852 | Dietrich et al. | Feb 2008 | A1 |
| 20080058871 | Libbus et al. | Mar 2008 | A1 |
| 20080103407 | Bolea et al. | May 2008 | A1 |
| 20080140138 | Ivanova et al. | Jun 2008 | A1 |
| 20080183226 | Buras et al. | Jul 2008 | A1 |
| 20080183246 | Patel et al. | Jul 2008 | A1 |
| 20080195171 | Sharma | Aug 2008 | A1 |
| 20080208266 | Lesser et al. | Aug 2008 | A1 |
| 20080213331 | Gelfand et al. | Sep 2008 | A1 |
| 20080234790 | Bayer et al. | Sep 2008 | A1 |
| 20080281365 | Tweden et al. | Nov 2008 | A1 |
| 20080281372 | Libbus et al. | Nov 2008 | A1 |
| 20090012590 | Inman et al. | Jan 2009 | A1 |
| 20090048194 | Aerssens et al. | Feb 2009 | A1 |
| 20090082832 | Carbunaru et al. | Mar 2009 | A1 |
| 20090088821 | Abrahamson | Apr 2009 | A1 |
| 20090105782 | Mickle et al. | Apr 2009 | A1 |
| 20090112291 | Wahlstrand et al. | Apr 2009 | A1 |
| 20090123521 | Weber et al. | May 2009 | A1 |
| 20090125076 | Shuros et al. | May 2009 | A1 |
| 20090125079 | Armstrong et al. | May 2009 | A1 |
| 20090143831 | Huston et al. | Jun 2009 | A1 |
| 20090171405 | Craig | Jul 2009 | A1 |
| 20090177112 | Gharib et al. | Jul 2009 | A1 |
| 20090187231 | Errico et al. | Jul 2009 | A1 |
| 20090210042 | Kowalczewski | Aug 2009 | A1 |
| 20090248097 | Tracey et al. | Oct 2009 | A1 |
| 20090254143 | Tweden et al. | Oct 2009 | A1 |
| 20090275997 | Faltys et al. | Nov 2009 | A1 |
| 20090276019 | Perez et al. | Nov 2009 | A1 |
| 20090281593 | Errico et al. | Nov 2009 | A9 |
| 20090312817 | Hogle et al. | Dec 2009 | A1 |
| 20100003656 | Kilgard et al. | Jan 2010 | A1 |
| 20100010556 | Zhao et al. | Jan 2010 | A1 |
| 20100010571 | Skelton et al. | Jan 2010 | A1 |
| 20100010581 | Goetz et al. | Jan 2010 | A1 |
| 20100010603 | Ben-David et al. | Jan 2010 | A1 |
| 20100016746 | Hampton et al. | Jan 2010 | A1 |
| 20100042186 | Ben-David et al. | Feb 2010 | A1 |
| 20100063563 | Craig | Mar 2010 | A1 |
| 20100074934 | Hunter | Mar 2010 | A1 |
| 20100191304 | Scott | Jul 2010 | A1 |
| 20100215632 | Boss et al. | Aug 2010 | A1 |
| 20100241183 | DiLorenzo | Sep 2010 | A1 |
| 20100241207 | Bluger | Sep 2010 | A1 |
| 20100249859 | DiLorenzo | Sep 2010 | A1 |
| 20100280562 | Pi et al. | Nov 2010 | A1 |
| 20100280569 | Bobillier et al. | Nov 2010 | A1 |
| 20110004266 | Sharma | Jan 2011 | A1 |
| 20110054569 | Zitnik et al. | Mar 2011 | A1 |
| 20110066208 | Pasricha et al. | Mar 2011 | A1 |
| 20110082515 | Libbus et al. | Apr 2011 | A1 |
| 20110092882 | Firlik et al. | Apr 2011 | A1 |
| 20110144717 | Burton et al. | Jun 2011 | A1 |
| 20110152967 | Simon et al. | Jun 2011 | A1 |
| 20110224749 | Ben-David et al. | Sep 2011 | A1 |
| 20110247620 | Armstrong et al. | Oct 2011 | A1 |
| 20110275927 | Wagner et al. | Nov 2011 | A1 |
| 20110301658 | Yoo et al. | Dec 2011 | A1 |
| 20110307027 | Sharma et al. | Dec 2011 | A1 |
| 20120053657 | Parker et al. | Mar 2012 | A1 |
| 20120065706 | Vallapureddy et al. | Mar 2012 | A1 |
| 20120179219 | Kisker et al. | Jul 2012 | A1 |
| 20120185009 | Kornet et al. | Jul 2012 | A1 |
| 20120185020 | Simon et al. | Jul 2012 | A1 |
| 20120296176 | Herbst | Nov 2012 | A1 |
| 20130013016 | Diebold | Jan 2013 | A1 |
| 20130018439 | Chow et al. | Jan 2013 | A1 |
| 20130066392 | Simon et al. | Mar 2013 | A1 |
| 20130066395 | Simon et al. | Mar 2013 | A1 |
| 20130245718 | Birkholz et al. | Sep 2013 | A1 |
| 20130317580 | Simon et al. | Nov 2013 | A1 |
| 20140046407 | Ben-Ezra et al. | Feb 2014 | A1 |
| 20140206945 | Liao | Jul 2014 | A1 |
| 20140257425 | Arcot-Krishnamurthy et al. | Sep 2014 | A1 |
| 20140277260 | Khalil et al. | Sep 2014 | A1 |
| 20140288551 | Bharmi et al. | Sep 2014 | A1 |
| 20140330335 | Errico et al. | Nov 2014 | A1 |
| 20150018728 | Gross et al. | Jan 2015 | A1 |
| 20150119956 | Libbus et al. | Apr 2015 | A1 |
| 20150133717 | Ghiron et al. | May 2015 | A1 |
| 20150180271 | Angara et al. | Jun 2015 | A1 |
| 20150233904 | Nayak | Aug 2015 | A1 |
| 20150241447 | Zitnik et al. | Aug 2015 | A1 |
| 20160067497 | Levine et al. | Mar 2016 | A1 |
| 20160114165 | Levine et al. | Apr 2016 | A1 |
| 20160250097 | Tracey et al. | Sep 2016 | A9 |
| 20160331952 | Faltys et al. | Nov 2016 | A1 |
| 20160367808 | Simon et al. | Dec 2016 | A9 |
| 20170202467 | Zitnik et al. | Jul 2017 | A1 |
| 20170304621 | Malbert et al. | Oct 2017 | A1 |
| 20180001096 | Faltys et al. | Jan 2018 | A1 |
| 20180021217 | Tracey et al. | Jan 2018 | A1 |
| 20180021580 | Tracey et al. | Jan 2018 | A1 |
| 20180085578 | Rennaker, II et al. | Mar 2018 | A1 |
| 20180117320 | Levine et al. | May 2018 | A1 |
| 20180289970 | Faltys et al. | Oct 2018 | A1 |
| 20190010535 | Pujol Onofre et al. | Jan 2019 | A1 |
| 20190022389 | Leonhardt | Jan 2019 | A1 |
| 20190046799 | Levine et al. | Feb 2019 | A1 |
| 20190111263 | Levine et al. | Apr 2019 | A1 |
| 20190192847 | Faltys et al. | Jun 2019 | A1 |
| 20190275328 | Zitnik et al. | Sep 2019 | A1 |
| 20200094055 | Manogue | Mar 2020 | A1 |
| 20200206515 | Faltys et al. | Jul 2020 | A1 |
| 20200238078 | Faltys et al. | Jul 2020 | A1 |
| 20220040483 | Levine et al. | Feb 2022 | A1 |
| 20220118257 | Huston et al. | Apr 2022 | A1 |
| 20220193413 | Levine et al. | Jun 2022 | A1 |
| Number | Date | Country |
|---|---|---|
| 201230913 | May 2009 | CN |
| 101528303 | Sep 2009 | CN |
| 101578067 | Nov 2009 | CN |
| 101868280 | Oct 2010 | CN |
| 104220129 | Dec 2014 | CN |
| 2628045 | Jan 1977 | DE |
| 3736664 | May 1989 | DE |
| 20316509 | Apr 2004 | DE |
| 0438510 | Aug 1996 | EP |
| 0726791 | Jun 2000 | EP |
| 1001827 | Jan 2004 | EP |
| 2213330 | Aug 2010 | EP |
| 2073896 | Oct 2011 | EP |
| 04133 | Feb 1910 | GB |
| 2073428 | Oct 1981 | GB |
| 20050039445 | Apr 2005 | KR |
| WO9301862 | Feb 1993 | WO |
| WO9730998 | Aug 1997 | WO |
| WO9820868 | May 1998 | WO |
| WO0027381 | May 2000 | WO |
| WO0047104 | Aug 2000 | WO |
| WO0100273 | Jan 2001 | WO |
| WO0108617 | Feb 2001 | WO |
| WO0189526 | Nov 2001 | WO |
| WO0244176 | Jun 2002 | WO |
| WO02057275 | Jul 2002 | WO |
| WO03072135 | Sep 2003 | WO |
| WO2004000413 | Dec 2003 | WO |
| WO2004064918 | Aug 2004 | WO |
| WO2006073484 | Jul 2006 | WO |
| WO2006076681 | Jul 2006 | WO |
| WO2007133718 | Nov 2007 | WO |
| WO2010005482 | Jan 2010 | WO |
| WO2010067360 | Jun 2010 | WO |
| WO2010118035 | Oct 2010 | WO |
| WO2016134197 | Aug 2016 | WO |
| Entry |
|---|
| US 6,184,239 B1, 02/2001, Puskas (withdrawn) |
| Abraham, Coagulation abnormalities in acute lung injury and sepsis, Am. J. Respir. Cell Mol. Biol., vol. 22(4), pp. 401-404, Apr. 2000. |
| Aekerlund et al., Anti-inflammatory effects of a new tumour necrosis factor-alpha (TNF-Alpha) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats, Clinical & Experimental Immunology, vol. 115, No. 1, pp. 32-41, Jan. 1, 1999. |
| Anderson et al.; Reflex principles of immunological homeostasis; Annu. Rev. Immunol.; 30; pp. 313-335; Apr. 2012. |
| Antonica, A., et al., Vagal control of lymphocyte release from rat thymus, J. Auton. Nerv. Syst., vol. 48(3), pp. 187-197, Aug. 1994. |
| Asakura et al., Non-surgical therapy for ulcerative colitis, Nippon Geka Gakkai Zasshi, vol. 98, No. 4, pp. 431-437, Apr. 1997 (abstract only). |
| Beliavskaia et al.,“On the effects of prolonged stimulation of the peripheral segment of the vagus nerve . . . ,” Fiziologicheskii Zhurnai SSSR Imeni I.M. Sechenova., vol. 52(11); p. 1315-1321, Nov. 1966. |
| Ben-Noun et al.; Neck circumference as a simple screening measure for identifying overweight and obese patients; Obesity Research; vol. 9; No. 8; pp. 470-477; Aug. 8, 2001. |
| Benoist, et al., “Mast cells in autoimmune disease” Nature., vol. 420(19): pp. 875-878, Dec. 2002. |
| Benthem et al.; Parasympathetic inhibition of sympathetic neural activity to the pancreas; Am.J.Physiol Endocrinol.Metab; 280(2); pp. E378-E381; Feb. 2001. |
| Bernik et al., Vagus nerve stimulation attenuates cardiac TNF production in endotoxic shock, (supplemental to SHOCK, vol. 15, 2001, injury, inflammation and sepsis: laboratory and clinicai approaches, SHOCK, Abstracts, 24th Annual Conference on Shock, Marco Island, FL, Jun. 9-12, 2001), Abstract No. 81. |
| Bernik et al., Vagus nerve stimulation attenuates endotoxic shock and cardiac TNF production, 87th Clinical Congress of the American College of Surgeons, New Orleans, LA, Oct. 9, 2001. |
| Bernik et al., Vagus nerve stimulation attenuates LPS-induced cardiac TNF production and myocardial depression IN shock, New York Surgical Society, New York, NY, Apr. 11, 2001. |
| Bernik, et al., Pharmacological stimulation of the cholinergic anti-inflammatory pathway, The Journal of Experimental Medicine, vol. 195, No. 6, pp. 781-788, Mar. 18, 2002. |
| Besedovsky, H., et al., Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones, Science, vol. 233, No. 4764, pp. 652-654, Aug. 1986. |
| Bhattacharya, S.K. et al., Central muscarinic receptor subtypes and carrageenin-induced paw oedema in rats, Res. Esp. Med. vol. 191(1), pp. 65-76, Dec. 1991. |
| Bianchi et al., Suppression of proinflammatory cytokines in monocytes by a tetravalent guanyihydrazone, Journal of Experimental Medicine, vol. 183, pp. 927-936, Mar. 1996. |
| Biggio et al.; Chronic vagus nerve stimulation induces neuronal plasticity in the rat hippocampus; Int. J. Neurpsychopharmacol.; vol. 12; No. 9; pp. 1209-1221; Oct. 2009. |
| Blackwell, T. S. et al., Sepsis and cytokines: current status, Br. J. Anaesth., vol. 77(1), pp. 110-117, Jul. 1996. |
| Blum. A. et al., Role of cytokines in heart failure, Am. Heart J., vol. 135(2), pp. 181-186, Feb. 1998. |
| Boldyreff, Gastric and Intestinal mucus, its properties and physiological Importance, Acta Medica Scandinavica (journal), vol. 89, Issue 1-2, pp. 1-14, Jan./Dec. 1936. |
| Borovikova et al., Acetylcholine inhibition of immune response to bacterial endotoxin in human macrophages. Abstracts, Society for Neuroscience, 29th Annual Meeting, Miami Beach, FL. (Abs. No. 624.6); Oct. 23-28, 1999. |
| Borovikova et al., Efferent vagus nerve activity attenuates cytokine-mediated inflammation, Society for Neuroscience Abstracts, vol. 26, No. 102, Nov. 4-9, 2000 (abstract only). |
| Borovikova et al., Intracerebroventricular CNI-1493 prevents LPS-induced hypotension and peak serum TNF at a four-log lower dose than systemic treatment, 21st Annual Conference on Shock, San Antonio, TX, Jun. 14-17, 1998, Abstract No. 86. |
| Borovikova et al., Role of the efferent vagus nerve signaling in the regulation of the innate immune response to LPS, (supplemental to SHOCK, vol. 13, 2000, Molecular, cellular, and systemic pathobiological aspects and therapeutic approaches, abstracts, 5th World Congress on Trauma, Shock inflammation and sepsis-pathophysiology, immune consequences and therapy, Feb. 29, 2000-Mar. 4, 2000, Munich, DE), Abstract No. 166. |
| Borovikova et al., Role of the vagus nerve in the anti-inflammatory effects of CNI-1493, the FASEB journal vol. 14, No. 4, 2000 (Experimental Biology 2000, San Diego, CA, 15-1 Apr. 8, 2000, Abstract No. 97.9). |
| Borovikova et al., Vagotomy blocks the protective effects I.C V. CNI-1493 against LPS-induced shock, (Supplemental to SHOCK, vol. 11, 1999, Molecular, cellular, and systemic pathobioloigal aspects and therapeutic approaches, abstacts and program, Fourth International Shock Congress and 22nd Annual Conference on Shock, Philadelphia, PA, Jun. 12-16, 1999), Abstract No. 277. |
| Borovikova, L. V., et al., Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation, Autonomic Neuroscience, vol. 85, No. 1-3, pp. 141-147, Dec. 20, 2000. |
| Borovikova, L. V., et al., Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin, Nature, vol. 405, No. 6785: pp. 458-462, May 25, 2000. |
| Bruchfeld et al.; Whole blood cytokine attenuation by cholinergic agonists ex vivo and relationship to vagus nerve activity in rheumatoid arthritis; J. Int. Med.; 268(1); pp. 94-101; Jul. 2010. |
| Bulloch et al.; Characterization of choline O-acetyltransferase (ChAT) in the BALB/C mouse spleen; Int.J.Neurosci.; 76(1-2); pp. 141-149; May 1994. |
| Bumgardner, G. L. et al., Transplantation and cytokines, Seminars in Liver Disease, vol. 19, No. 2, Thieme Medical Publishers; pp. 189-204, © 1999. |
| Burke et al., Beni pseudoknots and novel RNA inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase, J. Mol. Biol., vol. 264(4); pp. 650-666, Dec. 1996. |
| Bushby et al.; Centiles for adult head circumference; Archives of Disease in Childhood; vol. 67(10); pp. 1286-1287; Oct. 1992. |
| Cano et al.; Characterization of the central nervous system innervation of the rat spleen using viral transneuronal tracing; J.Comp Neurol.; 438(1); pp. 1-18; Oct. 2001. |
| Carteron, N. L., Cytokines in rheumatoid arthritis: trials and tribulations, Mol. Med. Today, vol. 6(8), pp. 315-323, Aug. 2000. |
| Cavaillon et al.; The pro-inflammatory cytokine casade; Immune Response in the Critically Ill; Springer-Verlag Berlin Hiedelberg; pp. 37-66; Jan. 21, 2002. |
| Cheyuo et al.; The parasympathetic nervous system in the quest for stroke therapeutics; J. Cereb. Blood Flow Metab.; 31(5); pp. 1187-1195; May 2011. |
| Cicala et al., “Linkage between inflammation and coagulation: An update on the molecular basis of the crosstalk,” Life Sciences, vol. 62(20); pp. 1817-1824, Apr. 1998. |
| Clark et al.; Enhanced recognition memory following vagus nerve stimulation in human subjects; Nat. Neurosci.; 2(1); pp. 94-98; Jan. 1999. |
| Cohen, “The immunopathogenesis of sepsis,” Nature., vol. 420(6917): pp. 885-891, Dec. 2002. |
| Corcoran, et al., The effects of vagus nerve stimulation on pro- and anti-inflammatory cytokines in humans: a preliminary report, NeuroImmunoModulation, vol. 12(5), pp. 307-309, Sep. 2005. |
| Crusz et al.; Inflammation and cancer; advances and new agents; Nature reviews Clinical Oncology; 12(10); pp. 584-596; doi: 10.1038/nrclinonc.2015.105; Jun. 30, 2015. |
| Dake; Chronic cerebrospinal venous insufficiency and multiple sclerosis: Hostory and background; Techniques Vasc. Intervent. Radiol.; 15(2); pp. 94-100; Jun. 2012. |
| Das, Critical advances in spticemia and septic shock, Critical Care, vol. 4, pp. 290-296, Sep. 7, 2000. |
| Del Signore et al.; Nicotinic acetylcholine receptor subtypes in the rat sympathetic ganglion: pharmacological characterization, subcellular distribution and effect of pre- and postganglionic nerve crush; J.Neuropathol.Exp.Neurol.; 63(2); pp. 138-150; Feb. 2004. |
| Diamond et al.; Mapping the immunological homunculus; Proc. Natl. Acad. Sci. USA; 108(9); pp. 3461-3462; Mar. 1, 2011. |
| Dibbs, Z., et al., Cytokines in heart failure: pathogenetic mechanisms and potential treatment, Proc. Assoc. Am. Physicians, vol. 111, No. 5, pp. 423-428, Sep.-Oct. 1999. |
| Dinarello, C. A., The interleukin-1 family: 10 years of discovery, FASEB J., vol. 8, No. 15, pp. 1314-1325, Dec. 1994. |
| Dorr et al.; Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission; J. Pharmacol. Exp. Ther.; 318(2); pp. 890-898; Aug. 2006. |
| Doshi et al., Evolving role of tissue factor and its pathway inhibitor, Crit. Care Med., vol. 30, suppl. 5, pp. S241-S250, May 2002. |
| Elenkov et al.; Stress, corticotropin-releasing hormone, glucocorticoids, and the immune / inflammatory response: acute and chronic effects; Ann. N.Y. Acad. Sci.; 876; pp. 1-13; Jun. 22, 1999. |
| Ellington et al., In vitro selection of RNA molecules that bind specific ligands, Nature, vol. 346, pp. 818-822, Aug. 30, 1990. |
| Ellrich et al.: Transcutaneous vagus nerve stimulation; Eur. Neurological Rev.; 6(4); pp. 254-256; Winter 2011. |
| Engineer et al.: Directing neural plasticity to understand and treat tinnitus; Hear. Res.; 295; pp. 58-66; Jan. 2013. |
| Engineer et al.; Reversing pathological neural activity using targeted plasticity; Nature; 470(7332); pp. 101-104; Feb. 3, 2011 (Author Manuscript). |
| Esmon, The protein C pathway, Crit. Care Med., vol. 28, suppl. 9, pp. S44-S48, Sep. 2000. |
| Fields; New culprits in chronic pain; Scientific American; pp. 50-57; Nov. 2009. |
| Fleshner, M., et al., Thermogenic and corticosterone responses to intravenous cytokines (IL-1? and TNF-?) are attenuated by subdiaphragmatic vagotomy, J. Neuroimmunol., vol. 86(2), pp. 134-141, Jun. 1998. |
| Fox, D. A., Cytokine blockade as a new strategy to treat rheumatoid arthritis, Arch. Intern. Med., vol. 160, pp. 437-444, Feb. 28, 2000. |
| Fox, et al., Use of muscarinic agonists in the treatment of Sjorgren syndrome, Clin. Immunol., vol. 101, No. 3; pp. 249-263, Dec. 2001. |
| Fujii et al.; Simvastatin regulates non-neuronal cholinergic activity in T lymphocytes via CD11a-mediated pathways; J. Neuroimmunol.; 179(1-2); pp. 101-107; Oct. 2006. |
| Gao et al.; Investigation of specificity of auricular acupuncture points in regulation of autonomic function in anesthetized rats; Autonomic Neurosc.; 138(1-2); pp. 50-56; Feb. 29, 2008. |
| Gattorno, M., et al., Tumor necrosis factor induced adhesion molecule serum concentrations in henoch-schoenlein purpura and pediatric systemic lupus erythematosus. J. Rheumatol., vol. 27, No. 9, pp. 2251-2255, Sep. 2000. |
| Gaykema R. P., et al., Subdiaphragmatic vagotomy suppresses endotoxin-induced activation of hypothalamic corticotropin-releasing hormone neurons and ACTH secretion, Endocrinology, vol. 136, No. 10, pp. 4717-4720, Oct. 1995. |
| Ghelardini et al., S-(-)-ET 126: A potent and selective M1 antagonist in vitro and in vivo, Life Sciences, vol. 58, No. 12, pp. 991-1000, Feb. 1996. |
| Ghia, et al., The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model, Gastroenterology, vol. 131, No. 4, pp. 1122-1130, Oct. 2006. |
| Giebelen, et al., Stimulation of ?7 cholinergic receptors inhibits lipopolysaccharide-induced neutrophil recruitment by a tumor necrosis factor ?-independent mechanism, SHOCK, vol. 27, No. 4, pp. 443-447, Apr. 2007. |
| Goyal et al., Nature of the vagal inhibitory innervation to the lower esophageal sphincter, Journal of Clinical Investigation, vol. 55, pp. 1119-1126, May 1975. |
| Gracie, J. A., et al., A proinflammatory role for IL-18 in rheumatoid arthritis, J. Clin. Invest., vol. 104, No. 10, pp. 1393-1401, Nov. 1999. |
| Granert et al., Suppression of macrophage activation with CNI-1493 increases survival in infant rats with systemic haemophilus influenzae infection, Infection and immunity, vol. 68, No. 9, pp. 5329-5334, Sep. 2000. |
| Green et al., Feedback technique for deep relaxation, Psycophysiology, vol. 6, No. 3, pp. 371-377, Nov. 1969. |
| Gregory et al., Neutrophil-kupffer-cell interaction in host defenses to systemic infections, Immunology Today, vol. 19, No. 11, pp. 507-510, Nov. 1998. |
| Groves et al.; Recordings from the rat locus coeruieus during acute vagal nerve stimulation in the anaesthetised rat; Neuroscience Letters; 379(3); pp. 174-179; May 13, 2005. |
| Guarente, Leonard, Ph. D.; Sirtuins, Aging, and Medicine; N Engl J Med ; vol. 364;pp. 2235-2244; Jun. 2011. |
| Guslandi, M., Nicotine treatment for ulcerative colitis, Br. J. Clin. Pharmacol., vol. 48(4), pp. 481-484, Oct. 1999. |
| Hansson, E.; Could chronic pain and spread of pain sensation be induced and maintained by glial activation?. Acta Physiologica, vol. 187, Issue 1-2; p. 321R327, May/Jun. 2006. |
| Harrison's Principles of Internal Medicine, 13th Ed., pp. 511-515 and 1433-1435, Mar. 1994. |
| Hatton et al.; Vagal nerve stimulation: overview and implications for anesthesiologists; Int'l Anesthesia Research Society; vol. 103; No. 5; pp. 1241-1249: Nov. 2006. |
| Hirano, T., Cytokine suppresive agent improves survival rate in rats with acute pancreatitis of closed duodenal loop, J. Surg. Res., vol. 81, No. 2, pp. 224-229, Feb. 1999. |
| Hirao et al., The limits of specificity: an experimental analysis with RNA aptamers to MS2 coat protein variants, Mol. Divers., vol. 4, No. 2, pp. 75-89, 1999 (Accepted Jan. 13, 1999). |
| Hoffer et al.; Implantable electrical and mechanical interfaces with nerve and muscle; Annals of Biomedical Engineering; vol. 8; pp. 351-360; Jul. 1980. |
| Holladay et al., Neuronal nicotinic acetylcholine receptors as targets for drug discovery, Journal of Medicinal Chemistry, 40(26), pp. 4169-4194, Dec. 1997. |
| Hommes, D. W et al.. Anti- and Pro-inflammatory cytokines in the pathogenesis of tissue damage in Crohn's disease, Current Opinion in Clinical Nutrition and Metabolic Care, vol. 3(3), pp. 191-195, May 2000. |
| Housley et al.; Biomarkers in multiple sclerosis; Clinical Immunology; 161 (1); pp. 51-58; Nov. 2015. |
| Hsu, et al., Analysis of efficiency of magnetic stimulation, IEEE Trans. Biomed. Eng., vol. 50(11), pp. 1276-1285, Nov. 2003. |
| Hsu, H. Y., et al., Cytokine release of peripheral blood monoculear cells in children with chronic hepatitis B virus infection, J. Pediatr. Gastroenterol., vol. 29, No. 5, pp. 540-545, Nov. 1999. |
| Hu, et al., The effect of norepinephrine on endotoxin-mediated macrophage activation, J. Neuroimmunol., vol. 31(1), pp. 35-42, Jan. 1991. |
| Huston et al.; Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis; J. Exp. Med. 2006; vol. 203, No. 7; pp. 1623-1628; Jun. 19, 2006. |
| Huston et al.; Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis; Crit. Care Med.; 35(12); pp. 2762-2768; Dec. 2007. |
| Hutchinson et al.; Proinflammatory cytokines oppose opioid induced acute and chronic analgesia; Brain Behav Immun.; vol. 22; No. 8; pp. 1178-1189; Nov. 2008. |
| Ilton et al., “Differential expression of neutrophil adhesion moiecuies during coronary artery surgery with cardiopulmonary bypass” Journal of Thoracic and Cardiovascular Surgery, Mosby—Year Book, inc., St. Louis, Mo, US, pp. 930-937, Nov. 1, 1999. |
| Jaeger et al., The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor, The EMBO Journal, 17(15), pp. 4535-4542, Aug. 1998. |
| Jander, S. et al., Interleukin-18 is induced in acute inflammatory demyelinating polymeuropathy, J. Neuroimmunol., vol. 114, pp. 253-258, Mar. 2001. |
| Joshi et al., Potent inhibition of human immunodeficiency virus type 1 replection by template analog reverse transcriptase , J. Virol., 76(13), pp. 6545-6557, Jul. 2002. |
| Kalishevskaya et al. “The character of vagotomy-and atropin-induced hypercoagulation,” Sechenov Physiological Journal of the USSR, 65(3): pp. 398-404, Mar. 1979. |
| Kalishevskaya et al.; Nervous regulation of the fluid state of the blood; Usp. Fiziol. Nauk;,vol. 13; No. 2; pp. 93-122; Apr.-Jun. 1982. |
| Kanai, T. et al., Interleukin-18 and Crohn's disease, Digestion, vol. 63, suppl. 1, pp. 37-42, (year of pub. sufficiently earlier than effective US filing date and any foreign priority date) 2001. |
| Katagiri, M., et al., Increased cytokine production by gastric mucosa in patients with helicobacter pylori infection, J. Clin, Gastroenterol., vol. 25, Suppl. 1, pp. S211-S214, 1997. |
| Katsavos et al.; Biomarkers in multiple sclerosis: an up-to-date overview; Multiple Sclerosis International; vol. 2013, Article ID 340508, 20 pages; (year of pub. sufficiently earlier than effective US filing date and any foreign priority date) 2013. |
| Kawahara et al.; SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span.; Cell. ; vol. 136; No. 1; pp. 62-74; Jan. 2009. |
| Kawashima, et al., Extraneuronal cholinergic system in lymphocytes, Pharmacology & Therapeutics, vol. 86, pp. 29-48, Apr. 2000. |
| Kees et al.; Via beta-adrenoceptors, stimulation of extrasplenic sympathetic nerve fibers inhibits lipopolysaccharide-induced TNF secretion in perfused rat spleen; J.Neuroimmunol.; 145(1-2); pp. 77-85; Dec. 2003. |
| Kensch et al., HIV- reverse transcriptase-pseudoknot RNA aptamer interaction has a binding affinity in the low picomolar range coupled with high specificity, J. Biol. Chem., 275(24), pp. 18271-18278, Jun. 16, 2000. |
| Khatun, S., et al., “Induction of hypercoagulability condition by chronic localized cold stress in rabbits,” Thromb. and Haemost., 81(3): pp. 449-455, Mar. 1999. |
| Kimball, et al., Levamisole causes differential cytokine expression by elicited mouse peritoneal macrophases, Journal of Leukocyte Biology, vo. 52, No. 3, pp. 349-356, Sep. 1992 (abstract only). |
| Kimmings, A. N., et al., Systemic inflammatory response in acute cholangitis and after subsequent treatment, Eur. J. Surg., vol. 166, pp. 700-705, Sep. 2000. |
| Kirchner et al.: Left vagus nerve stimulation suppresses experimentally induced pain; Neurology; vol. 55; pp. 1167-1171; Oct. 2000. |
| Kokkula, R. et at, Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity, Arthritis Rheum., 48(7), pp. 2052-2058, Jul. 2003. |
| Koopman et al.; Pilot study of stimulation of the cholinergic anti-inflammatory pathway with an implantable vagus nerve stimulation device in patients with rheumatoid arthritis; Arth. Rheum.; 64(10 suppl); pp. S195; Oct. 2012. |
| Krarup et al.; Conduction studies in peripheral cat nerve using implanted electrodes: I. methods and findings in controls; Muscle & Nerve; vol. 11; pp. 922-932; Sep. 1988. |
| Kudrjashov, et al. “Reflex nature of the physiological anticoagulating system,” Nature, vol. 196(4855): pp. 647-649; Nov. 17, 1962. |
| Kumins, N. H., et al., Partial hepatectomy reduces the endotoxin-induced peak circulating level of tumor necrosis factor in rats, SHOCK, vol. 5, No. 5, pp. 385-388, May 1996. |
| Kuznik, “Role of the vascular wall in the procsss of hemostatis,” Usp Sovrem Biol., vol. 75(1): pp. 61-85, (year of pub. sufficiently earlier than effective US filing date and any foreign priority date)1973. |
| Kuznik, et al., “Blood Coagulation in stimulation of the vagus nerve in cats,” Biull. Eskp. Biol. Med., vol. 78 (7): pp. 7-9, (year of pub. sufficiently earlier than effective US filing date and any foreign priority date) 1974. |
| Kuznik, et al., “Heart as an efferent regulator of the process of blood coagulation and fibrinolysis,” Kardiologiia, vol. 13(3): pp. 10-17, (year of pub. sufficiently earlier than effective US filing date and any foreign priority date) 1973. |
| Kuznik, et al., “Role of the heart and vessels in regulating blood coagulation and fibrinolysis,” Kagdiologiia, vol. 13(4): pp. 145-154, Apr. 1973. |
| Kuznik, et al., “Secretion of blood coagulation factors into saliva under conditions of hypo-and hypercoagulation,” Voprosy Meditsinskoi Khimii, vol. 19(1): pp. 54-57; (year of pub. sufficiently earlier than effective US filing date and any foreign priority date) 1973. |
| Kuznik, et al., “The dynamics of procoaguiatible and fibrinolytic activities during electrical stimulation of peripheral nerves,” Sechenov Physiological Journal of the USSR, vol. 65; No. 3: pp. 414-420, Mar. 1979. |
| Kuznik, et al., “The role of the vascular wail in the mechanism of control of blood coagulation and fibrinolysis on stimulation of the vagus nerve,” Cor Vasa, vol. 17(2): pp. 151-158, (year of pub. sufficiently earlier than effective US filing date and any foreign priority date) 1975. |
| Lang, et al., “Neurogienic control of cerebral blood flow,” Experimental Neurology, 43(1): pp. 143-161, Apr. 1974. |
| Lee, H. G., et al., Peritoneal lavage fluids stimulate NIH3T3 fibroblast proliferation and contain increased tumour necrosis factor and IL6 in experimental silica-induced rat peritonitis, Clin. Exp. Immunol., vol. 100, pp. 139-144, Apr. 1995. |
| LeNovere, N. et al., Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells, J. Mol. Evol., 40, pp. 155-172, Feb. 1995. |
| Leonard, S. et al., Neuronal nicotinic receptors: from structure to function, Nicotine & Tobacco Res. 3:203-223, Aug. 2001. |
| Lips et al.; Coexpression and spatial association of nicotinic acelylcholine receptor subunits alpha7 and alpha10 in rat sympathetic neurons; J.Mol.Neurosci.; 30; pp. 15-16; Feb. 2006. |
| Lipton, J. M. et al.; Anti-inflammatory actions of the neuroimmunomodulator ?-MSH, Immunol. Today, vol. 18, pp. 140-145, Mar. 1997. |
| Loeb et al.; Cuff electrodes for chronic stimulation and recording of peripheral nerve activity; Journal of Neuroscience Methods; vol. 64; pp. 95-103; Jan. 1996. |
| Madretsma, G. S., et al., Nicotine inhibits the in vitro production of interleukin 2 and tumour necrosis factor-alpha by human monocuclear cells, Immunopharmacology, vol. 35, No. 1, pp. 47-51, Oct. 1996. |
| Manta et al.; Optimization of vagus nerve stimulation parameters using the firing activity of serotonin neurons in the rat dorsal raphe; European Neuropsychopharmacology; vol. 19; pp. 250-255; Jan. 2009 (doi: 10.1016/j.euroneuro.2008.12.001). |
| Martindale: The Extra Pharmacopoeia; 28th Ed. London; The Pharmaceutical Press; pp. 446-485; © 1982. |
| Martiney et al., Prevention and treatment of experimental autoimmune encephalomyelitis by CNI-1493, a macrophage-deactivating agent, Journal of Immunology, vol. 160, No. 11, pp. 5588-5595, Jun. 1, 1998. |
| McGuinness, P.H., et al., Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particulary interleukin 18) in chronic hepatitis C infection, Gut, vol. 48(2), pp. 260-269, Feb. 2000. |
| Miguel-Hidalgo, J.J.; The role of glial cells in drug abuse; Current Drug Abuse Reviews; vol. 2; No. 1; pp. 76-82; Jan. 2009. |
| Milligan et al.; Pathological and protective roles of glia in chronic pain; Nat Rev Neurosci.; vol. 10; No. 1; pp. 23-26; Jan. 2009. |
| Minnich et al.; Anti-cytokine and anti-inflammatory therapies for the treatment of severe sepsis; progress and pitfalls; Proceedings of the Nutrition Society; vol. 63(3); pp. 437-441; Aug. 2004. |
| Mishchenko, et al., “Coagulation of the blood and fibrinolyses In dogs during vagal stimulation,” Sechenov Physiological Journal of the USSR, vol. 61(1): pp. 101-107, 1975. |
| Mishchenko, “The role of specific adreno-and choline-receptors of the vascular wall in the regulation of blood coagulation in the stimulation of the vagus nerve,” Biull. Eskp. Biol. Med., vol. 78(8): pp. 19-22, 1974. |
| Molina et al., CNI-1493 attenuates hemodynamic and pro-inflammatory responses to LPS, Shock, vol. 10, No. 5, pp. 329-334, Nov. 1998. |
| Nadol et al., “Surgery of the Ear and Temporal Bone,” Lippinkott Williams & Wilkins, 2nd Ed., 2005, (Publication date: Sep. 21, 2004), p. 580. |
| Nagashima et al., Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life, J. Clin. Invest., 109, pp. 101-110, Jan. 2002. |
| Nathan, C. F., Secretory products of macrophages, J. Clin. Invest., vol. 79(2), pp. 319-326, Feb. 1987. |
| Navalkar et al.; Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis; Journal of the American College of Cardiology: vol. 37; No. 2; pp. 440-444; Feb. 2001. |
| Navzer et al.; Reversing pathological neural activity using targeted plasticity; Nature; 470(7332); pp. 101-104; Feb. 3, 2011. |
| Neuhaus et al.; P300 is enhanced in responders to vagus nerve stimulation for treatment of major depressive disorder; J. Affect. Disord.; 100(1-3); pp. 123-128; Jun. 2007. |
| Noguchi et al., Increases in Gastric acidity in response to electroacupuncture stimulation of hindlimb of anesthetized rats, Jpn. J. Physiol., 46(1), pp. 53-58, Feb. 1996. |
| Norton, Can ultrasound be used to stimulate nerve tissue, BioMedical Engineering Online, 2(1), pp. 6, Mar. 4, 2003. |
| Olofsson et al.; Rethinking inflammation: neural circuits in the regulation of immunity; Immunological Reviews; 248(1); pp. 188-204; Jul. 2012. |
| Oshinsky et al.; Non-invasive vagus nerve stimulation as treatment for trigeminal allodynia; Pain; 155(5); pp. 1037-1042; May 2014. |
| Palmblad et al., Dynamics of early synovial cytokine expression in rodent collagen-induced arthritis: a thereapeutic study unding a macrophage-deactivation compound, American Journai of Pathology, vol. 158, No. 2, pp. 491-500, Feb. 2, 2001. |
| Pateyuk et al.,“Treatment of Botkin's disease with heparin,” Klin. Med., vol. 51(3): pp. 113-117, Mar. 1973. |
| Pavlov et al.; Controlling inflammation: the cholinergic anti-inflammatory pathway; Biochem. Soc. Trans.; 34(Pt 6); pp. 1037-1040; Dec. 2006. |
| Payne, J. B. et al., Nicotine effects on PGE2 and IL-1 beta release by LPS-treated human monocytes, J. Perio. Res., vol. 31, No. 2, pp. 99-104, Feb. 1996. |
| Peuker; The nerve supply of the human auricle; Clin. Anat.; 15(1); pp. 35-37; Jan. 2002. |
| Pongratz et al.; The sympathetic nervous response in inflammation; Arthritis Research and Therapy; 16(504); 12 pages; retrieved from the internet (http://arthritis-research.com/content/16/6/504) ; Jan. 2014. |
| Prystowsky, J. B. et al., Interleukin-1 mediates guinea pig gallbladder inflammation in vivo, J. Surg. Res., vol. 71, No. 2, pp. 123-126, Aug. 1997. |
| Pulkki, K. J., Cytokines and cardiomyocyte death, Ann. Med., vol. 29(4), pp. 339-343, Aug. 1997. |
| Pullan, R. D., et al., Transdermai nicotine for active ulceratiive colitis, N. Engl. J. Med., vol. 330, No. 12, pp. 811-815, Mar. 24, 1994. |
| Pulvirenti et al.; Drug dependence as a disorder of neural plasticity:focus on dopamine and glutamate; Rev Neurosci.; vol. 12; No. 2; pp. 141-158; Apr./Jun. 2001. |
| Rahman et al.; Mammalian Sirt 1: Insights on its biological functions; Cell Communications and Signaling; vol. 9; No. 11; pp. 1-8; May 2011. |
| Rayner, S. A. et al., Local bioactive tumour necrosis factor (TNF) in comeal allotransplantation, Clin. Exp. Immunol., vol. 122, pp. 109-116, Oct. 2000. |
| Reale et al.; Treatment with an acetylcholinesterase inhibitor in alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines: J. Neuroimmunology; 148(1-2); pp. 162-171; Mar. 2004. |
| Rinner et al.; Rat lymphocytes produce and secrete acetylcholine in dependence of differentiation and activation; J.Neuroimmunol.; 81(1-2); pp. 31-37; Jan. 1998. |
| Robinson et al.; Studies with the Electrocardiograph on the Action of the Vagus Nerve on the Human Heart; J Exp Med; 14(3):21 7-234; Sep. 1911. |
| Romanovsky, A. A., et al.,The vagus nerve in the thermoregulatory response to systemic inflammation, Am. J. Physiol., vol. 273, No. 1 (part 2), pp. R407-R413, Jul. 1, 1997. |
| Saghizadeh et al.; The expression of TNF? by human muscle: J. Clin. Invest.; vol. 97; No. 4; pp. 1111-1116; Feb. 15, 1996. |
| Saindon et al.; Effect of cervical vagotomy on sympathetic nerve responses to peripheral interleukin-1 beta; Auton.Neuroscience Basic and Clinical; 87; pp. 243-248; Mar. 23, 2001. |
| Saito, Involvement of muscarinic M1 receptor in the central pathway of the serotonin-induced bezold-jarisch reflex in rats, J. Autonomic Nervous System, vol. 49, pp. 61-68, Sep. 1994. |
| Sanchez et al.; The development and function of memory regulatory t cells after acute viral infections; J. Immunol.; 189(6); pp. 2805-2814; Sep. 15, 2012. |
| Sandborn, W. J., et al., Transdermal nicotine for mildly to moderately active ulcerative colitis, Ann. Intern. Med, vol. 126, No. 5, pp. 364-371, Mar. 1, 1997. |
| Sato, E., et al., Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity, Am. J. Physiol., vol. 274, pp. L970-L979, Jun. 1998. |
| Sato, K.Z., et al. Diversity of mRNA expression for muscarinic acetylcholine receptor subtypes and neuronal nicotinic acetylcholine receptor subunits in human mononuclear Ieukosytes and leukemic cell lines, Neuroscience Letters, vol. 266, pp. 17-20, Apr. 30, 1999. |
| Scheinman, R. I., et al., Role of transcriptional activation of I?B? in mediation of immunosuppression by glucocorticoids, Science, vol. 270, No. 5234, pp. 283-286, Oct. 13, 1995. |
| Schneider et al., High-affinity ssDNA inhibitors of the review transcriptase of type 1 human immunodeficiency virus, Biochemistry, 34(29), pp. 9599-9610, Jul. 1995. |
| Shafer, Genotypic testing for human immunodeficiency virus type 1 drug resistance, Clinical Microbiology Reviews, vol. 15, pp. 247-277, Apr. 2002. |
| Shapiro et al.; Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery; Thromb Haemost; vol. 80(5); pp. 773-778; Nov. 1998. |
| Sher, M. E., et al., The influence of cigarette smoking on cytokine levels in patients with inflammatory bowel disease, Inflamm, Bowel Dis., vol. 5, No. 2, pp. 73-78, May 1999. |
| Shevach et al.; Regulatory T cells; Nature Reviews Immunology; 1 page; © 2010 retrieved from internet (http://www.nature.com/nri/posters/tregcells/nri1001_treg_poster.pdf) on Aug. 11, 2016 (Poster). |
| Shi et al.; Effects of efferent vagus nerve excitation on inflammatory response in heart tissue in rats with endotoxemia; vol. 15, No. 1; pp. 26-28; Jan. 2003 (Eng. Abstract). |
| Snyder et al., Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors; Nature Medicine, 5(1), pp. 64-70, Jan. 1999. |
| Sokratov, et al. “The role of choline arid adrenegic structures in regulation of renal excretion of hemocoagulating compounds into the urine,” Sechenov Physiological Journai of the USSR, vol. 63(12): pp. 1728-1732, 1977. |
| Stalcup et al., Endothelial cell functions in the hemodynamic responses to stress, Annals of the New York Academy of Sciences, vol. 401, pp. 117-131, Dec. 1982. |
| Steinlein, New functions for nicotine acetylcholine receptors?, Behavioural Brain Res., vol. 95(1), pp. 31-35, Sep. 1998. |
| Sternberg, E. M., Perspectives series: cytokines and the brain ‘neural-immune interactions in health and disease,’ J. Clin. Invest., vol. 100, No. 22, pp. 2641-2647, Dec. 1997. |
| Stevens et al.; The anti-inflammatory effect of some immunosuppressive agents; J. Path.; 97(2); pp. 367-373; Feb. 1969. |
| Strojnik et al.; Treatment of drop foot using and implantable peroneal underknee stimulator; Scand. J. Rehab. Med.; vol. 19(1); pp. 37R43; Dec. 1986. |
| Strowig et al.; Inflammasomes in health and disease; Nature; vol. 481; pp. 278-286; doi: 10.1038/nature10759; Jan. 19, 2012. |
| Sugano et al., Nicotine inhibits the production of inflammatory mediators in U937 cells through modulation of nuclear factor-kapparβ activation, Biochemical and Biophysical Research Communications, vol. 252, No. 1, pp. 25-28, Nov. 9, 1998. |
| Suter et al.; Do glial cells control pain?; Neuron Glia Biol.; vol. 3; No. 3; pp. 255-268; Aug. 2007. |
| Swick et al.; Locus coeruieus neuronal activity in awake monkeys: relationship to auditory P300-like potentials and spontaneous EEG. Exp. Brain Res.; 101(1); pp. 86-92; Sep. 1994. |
| Sykes, et al., An investigation into the effect and mechanisms of action of nicotine in inflammatory bowel disease, Inflamm. Res., vol. 49, pp. 311-319, Jul. 2000. |
| Takeuchi et al., A comparision between Chinese blended medicine “Shoseiryuto”tranilast and ketolifen on the anit-allergic action in the guinea pigs, Allergy, vol. 34, No. 6, pp. 387-393, Jun. 1985 (eng. abstract). |
| Tekdemir et al.; A clinico-anatomic study of the auricular branch of the vagus nerve and arnold's ear-cough reflex; Surg. Radiol. Anat.; 20(4); pp. 253-257; Mar. 1998. |
| Toyabe, et al., Identification of nicotinic acetylcholine receptors on lymphocytes in the periphery as well as thymus in mice, Immunology, vol. 92(2), pp. 201-205, Oct. 1997. |
| Tracey et al., Mind over immunity, Faseb Journal, vol. 15, No. 9, pp. 1575-1576, Jul. 2001. |
| Tracey, K. J. et al., Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia; Nature, 330: pp. 662-664, Dec. 23, 1987. |
| Tracey, K. J. et al., Physiology and immunology of the cholinergic antiinflammatory pathway; J Clin Invest.; vol. 117: No. 2; pp. 289-296; Feb. 2007. |
| Tracey, K. J. et al., Shock and tissue injury induced by recombinant human cachectin, Science, vol. 234, pp. 470-474, Oct. 24, 1986. |
| Tracey, K. J.; Reflex control of immunity: Nat Rev Immunol; 9(6); pp. 418-428: Jun. 2009. |
| Tracey, K.J., The inflammatory reflex, Nature, vol. 420, pp. 853-859, Dec. 19-26, 2002. |
| Tsutsui, H., et al., Pathophysiolocical roles of interleukin-18 in inflammatory liver diseases; Immunol. Rev., 174:192-209, Apr. 2000. |
| Tuerk et al., RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase; Proc. Natl. Acad. Sci. USA, 89, pp. 6988-6992, Aug. 1992. |
| Tuerk et al., Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase; Science, 249(4968), pp. 505-510, Aug. 3, 1990. |
| Van Der Horst et al.; Stressing the role of FoxO proteins in lifespan and disease; Nat Rev Mol Cell Biol.; vol. 8; No. 6; pp. 440-450; Jun. 2007. |
| Van Dijk, A. P., et al., Transdermal nictotine inhibits interleukin 2 synthesis by mononuclear cells derived from healthy volunteers, Eur. J. Clin. Invest, vol. 28, pp. 664-671, Aug. 1998. |
| Vanhoutte, et al., Muscarinic and beta-adrenergic prejunctional modulation of adrenergic neurotransmission in the blood vessel wall, Gen Pharmac., vol. 14(1), pp. 35-37, Jan. 1983. |
| VanWesterloo, et al., The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis, The Journal of infectious Diseases, vol. 191, pp. 2138-2148, Jun. 15, 2005. |
| Venken et al.; Natural naive CD4+ CD25+ CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory treg homeostasis during disease progression, J. Immunol.; 180(9); pp. 6411-6420; May 2008. |
| Ventureyra, Transcutaneous vagus nerve stimulation for partial onset seizure therapy, Child's Nerv Syst, vol. 16(2), pp. 101-102, Feb. 2000. |
| Vijayaraghavan, S.; Glial-neuronal interactions-implications for plasticity anddrug addictlonl AAPS J.; vol. 11; No. 1; pp. 123-132; Mar. 2009. |
| Villa et al., Protection against lethal polymicrobial sepsis by CNI-1493, an inhibitor of pro-inflammatory cytokine synthesis, Journal of Endotoxin Research, vol. 4, No. 3, pp. 197-204, Jun. 1997. |
| Von Känel, et al., Effects of non-specific ?-adrenergic stimulation and blockade on blood coagulation in hypertension, J. Appl. Physiol., vol. 94, pp. 1455-1459, Apr. 2003. |
| Von Känel, et al., Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo, Eur. J. Haematol., vol. 65: pp. 357-369, Dec. 2000. |
| Walland et al., Compensation of muscarinic brochial effects of talsaclidine by concomitant sympathetic activation in guinea pigs; European Journal of Pharmacology, vol. 330(2-3), pp. 213-219, Jul. 9, 1997. |
| Wang et al; Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation; Nature; 421; 384-388: Jan. 23, 2003. |
| Wang, H., et al., HMG-1 as a late mediator of endotoxin lethality in mice, Science, vol. 285, pp. 248-251, Jul. 9, 1999. |
| Waserman, S. et al., TNF-? dysregulation in asthma: relationship to ongoing corticosteroid therapy, Can. Respir. J., vol. 7, No. 3, pp. 229-237, May-Jun. 2000. |
| Watanabe, H. et al., The significance of tumor necrosis factor (TNF) levels for rejection of joint allograft, J. Reconstr. Microsurg., vol. 13, No. 3, pp. 193-197, Apr. 1997. |
| Wathey, J.C. et al., Numerical reconstruction of the quantal event at nicotinic synapses; Biophys. J., vol. 27: pp. 145-164, Jul. 1979. |
| Watkins, L.R. et al., Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication, Neurosci. Lett., vol. 183(1-2), pp. 27-31, Jan. 1995. |
| Watkins, L.R. et al., Implications of immune-to-brain communication for sickness and pain, Proc. Natl. Acad. Sci. U.S.A., vol. 96(14), pp. 7710-7713, Jul. 6, 1999. |
| Webster's Dictionary, definition of “intrathecal”, online version accessed Apr. 21, 2009. |
| Weiner, et al., “Inflammation and therapeutic vaccination in CNS diseases,” Nature., vol. 420(6917): pp. 879-884, Dec. 19-26, 2002. |
| Westerheide et al.; Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1.; Science; Vo. 323; No. 5717; pp. 1063-1066; Feb. 2009. |
| Whaley, K. et al., C2 synthesis by human monocytes is modulated by a nicotinic cholinergic receptor, Nature, vol. 293, pp. 580-582, Oct. 15, 1981. |
| Woiciechowsky, C. et al., Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nature Med., vol. 4, No. 7, pp. 808-813, Jul. 1998. |
| Yeh, S.S. et al., Geriatric cachexia: the role of cytokines, Am. J. Clin. Nutr., vol. 70(2), pp. 183-197, Aug. 1999. |
| Yu et al.; Low-level transcutaneous electrical stimulation of the auricular branch of the vagus nerve: a non-invasive approach to treat the initial phase of atrial fibrillation; Heart Rhythm; 10(3), pp. 428-435; Mar. 2013. |
| Zamotrinsky et al.; Vagal neurostimulation in patients with coronary artery disease; Auton. Neurosci.; 88(1-2); pp. 109-116; Apr. 2001. |
| Zhang et al., Tumor necrosis factor, The Cytokine Handbook, 3rd ed., Ed. Thompson, Academic Press, pp. 517-548, Jul. 1, 1998. |
| Zhang et al.; Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model; Circulation Heart Fail; 2; pp. 692-699; Nov. 2009. |
| Zhang et al.; Roles of SIRT1 in the acute and restorative phases following induction of inflammation.; J Biol Chem.; vol. 285; No. 53; pp. 41391-41401; Dec. 2010. |
| Zhao et al.; Transcutaneous auricular vagus stimulation protects endotoxemic rat from lipopolysaccharide-induced inflammation; Evid. Based Complement Alternat. Med.; vol. 2012; Article ID 627023; 10 pages; Dec. 29, 2012. |
| Faltys et al.; U.S. Appl. No. 16/544,882 entitled “Neural stimulation devices and systems for treatment of chronic inflammation,” filed Aug. 19, 2019. |
| Tracey et al.; U.S. Appl. No. 17/170,772 entitled “Treatment of bleeding by non-invasive stimulation,” filed Feb. 8, 2021. |
| Palov et al.; The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation; Molecular Medicine; 9(5); pp. 125-134; May 2003. |
| Koopman et al.; THU0237 first-in-human study of vagus nerve stimulation for rheumatoid arthritis: clinical and biomarker results through day 84; Annals of the Rheumatic Diseases; 72(Suppl 3):A245: Jun. 1, 2013 (Abstract Only). |
| Koopman et al.; Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis; Proceedings of the National Academy of Sciences; 113(29); pp. 8284-8289; Jul. 19, 2016. |
| Mayo Clinic; The factsheet of vagus nerve stimulation from the Mayo Clinic website: www.mayoclinic.org/tests-procedures/vagus-nerve-stimulation/about/pac-20384565; retrieved from the internet on Sep. 28, 2021. |
| Levine et al.; U.S. Appl. No. 17/337,292 entitled “Closed-loop vagus nerve stimulation,” filed Jun. 2, 2021. |
| Faltys et al.; U.S. Appl. No. 17/443,875 entitled “Neural stimulation devices and systems for treatment of chronic inflammation,” filed Jul. 28, 2021. |
| Koopman et al., Pilot study of stimulation of the cholinergic anti-inflammatory pathway with an implantable vagus nerve stimulation device in patients with rheumatoid arthritis; 2012 ACR/ARHP Annual Meeting; Abstract No. 451; 4 pages; retrieved from the internet (https://acrabstracts.org/abstract/pilot-study-of-stimulation-of-the-cholinergic-anti-inflammatory-pathway-with-an-implantable-vagus-nerve-stimulation-device-in-patients-with-rheumatoid-arthritis); (Abstract Only); on Sep. 24, 2020. |
| Pavlov et al.; The cholinergic anti-inflammatory pathway; Brain, Behavior, and Immunity; 19; p. 493-499; Nov. 2005. |
| Zitnik et al.; Treatment of chronic Inflammatory diseases with implantable medical devices; Cleveland Clinic Journal of Medicine; 78(Suppl 1); pp. S30-S34; Aug. 2011. |
| Manogue; U.S. Appl. No. 17/578,339 entitled “Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation,” filed Jan. 18, 2022. |
| Faltys et al.; U.S. Appl. No. 17/700,415 entitled “Systems and methods for establishing a nerve block,” filed Mar. 21, 2022. |
| Number | Date | Country | |
|---|---|---|---|
| 20200330760 A1 | Oct 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62340950 | May 2016 | US | |
| 62286950 | Jan 2016 | US | |
| 62286957 | Jan 2016 | US | |
| 62281135 | Jan 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15411933 | Jan 2017 | US |
| Child | 16916036 | US |
